

CITATION REPORT

List of articles citing

**Aortocoronary saphenous vein graft disease:
pathogenesis, predisposition, and prevention**

**DOI: 10.1161/01.cir.97.9.916
Circulation, 1998, 97, 916-31.**

Source: <https://exaly.com/paper-pdf/29624066/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
945	Post-mortem examination after cardiac surgery. 1998 , 33, 399-405		12
944	Mouse model of venous bypass graft arteriosclerosis. 1998 , 153, 1301-10		198
943	Coronary artery surgery: the end of the beginning. 1998 , 14, 554-71		32
942	Endothelial dysfunction in human hand veins is rapidly reversible after smoking cessation. 1998 , 275, H1040-5		13
941	Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts. <i>Circulation</i> , 1999 , 99, 879-82	16.7	48
940	Cardiac bypass haemostasis: putting blood through the mill. 1999 , 104, 208-19		80
939	Alternative approach to multivessel coronary disease with integrated coronary revascularization. 1999 , 117, 439-44; discussion 444-6		50
938	Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. 1999 , 354, 1493-8		349
937	External support modulates G protein expression and receptor coupling in experimental vein grafts. 1999 , 126, 127-134		8
936	Inhibitory effects of beraprost on platelet aggregation: comparative study utilizing two methods of aggregometry. 1999 , 94, 25-32		13
935	Interesting cases from the University of Texas Medical Branch. 1999 , 17, 401-14		
934	Reduction of lipid peroxidation with intraoperative superoxide dismutase treatment decreases intimal hyperplasia in experimental vein grafts. 1999 , 84, 223-32		26
933	Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin. <i>Circulation</i> , 1999 , 100, 861-8	16.7	113
932	Factor Xa Acts as a PDGF-Independent Mitogen in Human Vascular Smooth Muscle Cells. 2000 , 84, 499-505		35
931	Urgent Smoking Cessation Interventions. 2000 , &NA;, 19-23		1
930	Lipid lowering and coronary bypass graft surgery. 2000 , 15, 395-9		24
929	S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. 2000 , 131, 1236-44		44

928	Intimal hyperplasia in vascular grafts. 2000 , 19, 336-50	154
927	Biomechanical-stress-induced signaling and gene expression in the development of arteriosclerosis. 2000 , 10, 35-41	65
926	Health Risk Reduction and Functional Restoration Following Coronary Revascularization: A Prospective Investigation Using Dynamic Stage Typology Clustering. 2000 , 5, 99-116	12
925	Nicotine impairs endothelium-dependent dilatation in human veins in vivo. 2000 , 67, 391-7	74
924	Transcriptional control of deformation-induced preproendothelin-1 gene expression in endothelial cells. 2000 , 78, 441-50	24
923	Endothelin and the "seventh inning stretch". 2000 , 78, 361-2	
922	Der Einfluss des Innendurchmessers der Koronararterie auf den Fluss durch einen aortokoronaren Venenbypass und seine Offenheitsrate. 2000 , 14, 65-69	
921	Biomechanical stress-induced apoptosis in vein grafts involves p38 mitogen-activated protein kinases. 2000 , 14, 261-70	134
920	Healing characteristics of small-calibre vascular prostheses coated with plasmin-treated fibrin--an experimental study. 2000 , 29, 117-24	6
919	Reduced neointima hyperplasia of vein bypass grafts in intercellular adhesion molecule-1-deficient mice. 2000 , 86, 434-40	77
918	Pressure-induced upregulation of preproendothelin-1 and endothelin B receptor expression in rabbit jugular vein in situ : implications for vein graft failure?. 2000 , 20, 96-103	59
917	Urgent Smoking Cessation Interventions. 2000 , 100, 19	2
916	Rapid and efficient vascular transport of arginine polymers inhibits myointimal hyperplasia. <i>Circulation</i> , 2000 , 102, 2629-35	16.7 18
915	Postscripts from the Post-Coronary Artery Bypass Graft trial: the sustained benefit of more aggressive cholesterol lowering and the enigma of low-dose anticoagulation. <i>Circulation</i> , 2000 , 102, 144 ^{16.7} -6	9
914	Vascular matrix and vein graft failure. Is the message in the medium?. <i>Circulation</i> , 2000 , 101, 221-3	16.7 67
913	Accelerated atherosclerosis by placement of a perivascular cuff and a cholesterol-rich diet in ApoE*3Leiden transgenic mice. 2000 , 87, 248-53	69
912	Percutaneous coronary intervention for patients with prior bypass surgery: therapy in evolution. 2000 , 108, 176-7	9
911	Rapid development of vein graft atheroma in ApoE-deficient mice. 2000 , 157, 659-69	68

910	Polymorphism of the transforming growth factor-beta 1 gene correlates with the development of coronary vasculopathy following cardiac transplantation. 2000 , 19, 551-6	58
909	Functional properties of the saphenous vein harvested by minimally invasive techniques. 2000 , 69, 1116-20	13
908	Functional assessment of disease-free saphenous vein grafts at redo coronary artery bypass grafting. 2000 , 69, 1183-7	12
907	The effect of image distortion on 3-D reconstruction of coronary bypass grafts from angiographic views. 2000 , 19, 759-62	6
906	Aneurysmal degeneration and late rupture of an aortorenal vein graft: case report, review of the literature, and implications for conduit selection. 2000 , 32, 612-5	20
905	Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators. 2000 , 36, 1877-83	98
904	VCAM-1 expression precedes macrophage infiltration into subendothelium of vein grafts interposed into carotid arteries in hypercholesterolemic rabbits--a potential role in vein graft atherosclerosis. 2001 , 158, 313-9	23
903	Suitability of venous and arterial conduits used for coronary artery bypass grafting in conjunction with coronary disease risk factors. 2001 , 80, 61-8	1
902	Non-hemostatic activity of coagulation factor Xa: potential implications for various diseases. 2001 , 1, 169-75	18
901	Immunohistochemical and ultrastructural evidence that dendritic cells infiltrate stenotic aortocoronary saphenous vein bypass grafts. 2001 , 9, 194-200	13
900	A novel organ culture method to study intimal hyperplasia at the site of a coronary artery bypass anastomosis. 2001 , 71, 1273-9; discussion 1279-80	10
899	Reversal of preexisting vasospasm in coronary artery conduits. 2001 , 72, 476-80	37
898	The coronary artery bypass conduit: I. Intraoperative endothelial injury and its implication on graft patency. 2001 , 72, S2245-52; discussion S2267-70	83
897	Potentiation of ibudilast inhibition of platelet aggregation in the presence of endothelial cells. 2001 , 102, 239-46	11
896	[Therapeutic control and quality of life in coronary artery bypass surgery patients]. 2001 , 116, 241-5	1
895	Gene therapy for vein graft disease. 2001 , 3, 22-8	2
894	Coronary Artery Bypass Graft Degenerative Disease. 2001 , 3, 47-54	2
893	Accelerated smooth muscle cell apoptosis in occluded aorto-coronary saphenous vein grafts. 2001 , 10, 237-240	

892	Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. 2001 , 59, 2325-34		262
891	Identification and mapping of human saphenous vein medial smooth muscle proteins by two-dimensional polyacrylamide gel electrophoresis. 2001 , 1, 1405-14		59
890	[MR angiography and flow measurement in coronary arteries and coronary bypass grafts]. 2001 , 90, 929-38		2
889	[Modified endothelial cells in graft vasculopathy]. 2001 , 90, 939-45		1
888	Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells. 2001 , 132, 1441-6		46
887	Cilostazol suppresses intimal formation in dog grafted veins with reduction of angiotensin II-forming enzymes. 2001 , 411, 301-4		3
886	Aspirin resistance after coronary artery bypass grafting. 2001 , 121, 982-4		82
885	Perivenous support reduces early changes in human vein grafts: studies in whole blood perfused human vein segments. 2001 , 121, 290-7		40
884	L-arginine polymers inhibit the development of vein graft neointimal hyperplasia. 2001 , 121, 971-80		38
883	Smooth muscle cell apoptosis in arteriosclerosis. 2001 , 36, 969-87		69
882	[Coronary artery bypass graft dysfunction--clinical presentation, laboratory and electrocardiographic parameters]. 2001 , 28, 5-10		
881	Non-penetrating vascular clips anastomosis inhibited intimal thickening under poor runoff conditions in canine autogenous vein grafts. 2001 , 21, 241-7		11
880	Natural course of the functional and morphological changes in canine autogenous arterial graft. 2001 , 33, 21-7		4
879	ACE inhibitor and AT1 antagonist blockade of deformation-induced gene expression in the rabbit jugular vein through B2 receptor activation. 2001 , 21, 61-6		14
878	Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. <i>Circulation</i> , 2001 , 103, 363-8	16.7	214
877	Local gene transfer of tissue inhibitor of metalloproteinase-2 influences vein graft remodeling in a mouse model. 2001 , 21, 1275-80		70
876	Autologous Endothelialized Vein Allograft. <i>Circulation</i> , 2001 , 104, I-108-I-114	16.7	55
875	Oxidative stress and lipid retention in vascular grafts: comparison between venous and arterial conduits. <i>Circulation</i> , 2001 , 103, 2408-13	16.7	50

874	Use of the internal mammary artery graft and in-hospital mortality and other adverse outcomes associated with coronary artery bypass surgery. <i>Circulation</i> , 2001 , 103, 507-12	16.7	80
873	Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. <i>Circulation</i> , 2001 , 103, 562-9	16.7	59
872	Adenoviral activin a expression prevents intimal hyperplasia in human and murine blood vessels by maintaining the contractile smooth muscle cell phenotype. 2002 , 90, 1128-34		32
871	Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. <i>Circulation</i> , 2002 , 105, 322-7	16.7	47
870	Accelerated atherosclerosis and calcification in vein grafts: a study in APOE*3 Leiden transgenic mice. 2002 , 91, 577-84		53
869	Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. <i>Circulation</i> , 2002 , 106, 3063-7	16.7	175
868	Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. <i>Circulation</i> , 2002 , 105, 1623-6	16.7	79
867	Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. 2002 , 22, 387-96		97
866	Platelet glycoprotein IIb/IIIa inhibition and atheroembolism during bypass graft angioplasty: a cup half full. <i>Circulation</i> , 2002 , 106, 2994-6	16.7	10
865	Both donor and recipient origins of smooth muscle cells in vein graft atherosclerotic lesions. 2002 , 91, e13-20		119
864	The hybrid approach to coronary artery revascularization: minimally invasive direct coronary artery bypass with percutaneous coronary intervention. 2002 , 53, 665-9		7
863	Nitric oxide synthase gene therapy for cardiovascular disease. 2002 , 89, 327-36		33
862	Treatment of totally occluded saphenous vein grafts using self-expanding stents. 2002 , 13, 373-6		2
861	Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure. 2002 , 90, 205-12		67
860	Neointimal hyperplasia rapidly reaches steady state in a novel murine vein graft model. 2002 , 36, 824-832		
859	Hemodialysis vascular access dysfunction from basic biology to clinical intervention. 2002 , 9, 74-84		31
858	Generation and characterisation of human saphenous vein endothelial cell lines. 2002 , 160, 59-67		14
857	In vivo vascular engineering of vein grafts: directed migration of smooth muscle cells by perivascular release of elastase limits neointimal proliferation. 2002 , 13, 709-15		22

856	Flow dynamics in internal thoracic artery grafts 10 years after coronary artery bypass grafting. 2002 , 73, 131-7	9
855	Gene transfer to coronary artery bypass conduits. 2002 , 74, 1161-6; discussion 1166	14
854	Proliferative activity in stenotic human aortocoronary bypass grafts. 2002 , 11, 284-90	11
853	Differences in endothelial function and morphologic modulation between canine autogenous venous and arterial grafts: endothelium and intimal thickening. 2002 , 131, S249-55	25
852	Neointimal hyperplasia rapidly reaches steady state in a novel murine vein graft model. 2002 , 36, 824-832	44
851	Accelerated atherosclerosis in saphenous vein bypass grafts: a spectrum of diffuse plaque instability. 2002 , 44, 437-48	21
850	Internal thoracic artery grafting in the elderly patient undergoing coronary artery bypass grafting: room for process improvement?. 2002 , 123, 869-80	39
849	An external, oversized, porous polyester stent reduces vein graft neointima formation, cholesterol concentration, and vascular cell adhesion molecule 1 expression in cholesterol-fed pigs. 2002 , 124, 950-6	51
848	Mechanical stress-induced apoptosis in the cardiovascular system. 2002 , 78, 105-37	43
847	Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. 2002 , 54, 587-606	235
846	Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. 2002 , 62, 2272-80	75
845	Improving the clinical patency of prosthetic vascular and coronary bypass grafts: the role of seeding and tissue engineering. 2002 , 26, 307-20	180
844	New mouse model of vein bypass graft atherosclerosis. 2002 , 11, 182-8	5
843	Magnetic resonance imaging for the non-invasive detection of stenosis in coronary artery bypass grafts: clinical reality?. 2002 , 18, 479-82	1
842	A method to isolate morphologically distinct clones of smooth muscle cells from human saphenous vein. 2002 , 24, 131-7	2
841	The agonist of the protease-activated receptor-1 (PAR) but not PAR3 mimics thrombin-induced vascular endothelial growth factor release in human smooth muscle cells. 2003 , 60, 1716-24	18
840	Characteristics of Patients with Patent versus Closed Left Internal Thoracic Artery Grafts before Redo Revascularization. 2003 , 35, 332-336	
839	Coagulation and fibrinolytic markers in a two-month follow-up of coronary bypass surgery. 2003 , 125, 336-43	37

838	Is there a hypercoagulable state after off-pump coronary artery bypass surgery? What do we know and what can we do?. 2003 , 126, 7-10	34
837	Association of lipoprotein(a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery. 2003 , 126, 1071-5	18
836	JTCVS on-line manuscript submission and review. 2003 , 126, 10	2
835	Relative risks of reported serious injury and death associated with hemostasis devices by gender. 2003 , 12, 237-41	5
834	Use of external iliac artery in renal revascularization surgery: long-term angiographic assessment. 2003 , 38, 123-8	1
833	Fibronectin-based masking molecule blocks platelet adhesion. 2003 , 14, 703-6	6
832	Intimal exuberance: veins in jeopardy. 2003 , 162, 1759-61	10
831	Increased venous proinflammatory gene expression and intimal hyperplasia in an aorto-caval fistula model in the rat. 2003 , 162, 2079-90	64
830	Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure. 2003 , 75, 1437-42	34
829	Pressure distension stimulates the expression of endothelial adhesion molecules in the human saphenous vein graft. 2003 , 76, 453-8; discussion 458	42
828	Arterial grafting results in reduced operative mortality and enhanced long-term quality of life in octogenarians. 2003 , 76, 418-26; discussion 427	39
827	Statins in coronary bypass surgery: rationale and clinical use. 2003 , 76, 2132-40	35
826	Angiographic changes in vein grafts: stable surrogate or seductive siren?. <i>American Heart Journal</i> , 2003 , 145, 187-9	4.9
825	Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention. <i>American Heart Journal</i> , 2003 , 145, 529-34	4.9 29
824	Advances in vascular tissue engineering. 2003 , 12, 271-6	107
823	Complications related to off-pump bypass grafting. 2003 , 15, 63-70	8
822	Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. <i>Circulation</i> , 2003 , 107, 490-7	16.7 703
821	cDNA cloning of rabbit thrombomodulin and characterization of gene expression in cardiovascular tissue. 2003 , 14, 399-405	4

820	Percutaneous treatment of saphenous vein bypass graft obstructions: a continuing obstinate problem. <i>Circulation</i> , 2003 , 107, 2284-6	16.7	37
819	Thrombosis of vein grafts: wall tension restrains thrombomodulin expression. 2003 , 92, 12-3		88
818	Pathology of coronary microembolisation and no reflow. 2003 , 89, 983-5		23
817	Gene expression profiling of human stenotic aorto-coronary bypass grafts by cDNA array analysis. 2003 , 23, 620-5		14
816	Value of magnetic resonance imaging for the noninvasive detection of stenosis in coronary artery bypass grafts and recipient coronary arteries. <i>Circulation</i> , 2003 , 107, 1502-8	16.7	68
815	Circulating progenitor cells regenerate endothelium of vein graft atherosclerosis, which is diminished in ApoE-deficient mice. 2003 , 93, e76-86		154
814	Influence of type 2 diabetes on functional and structural properties of coronary artery bypass conduits. 2003 , 52, 2814-20		47
813	Diameter changes of occluded venous coronary artery bypass grafts in electron beam tomography: preliminary findings. 2003 , 23, 347-53		8
812	Apoptosis and histopathologic changes in diffuse coronary atherosclerosis. 2003 , 54, 81-4		1
811	Hemodialysis vascular access dysfunction: from pathophysiology to novel therapies. 2003 , 21, 99-110		93
810	Break the Cycle: The Role of Cell-Cycle Modulation in the Prevention of Vasculoproliferative Diseases. 2003 , 2, 210-218		18
809	Vein graft function improvement after percutaneous intervention: evaluation with MR flow mapping. 2003 , 228, 834-41		11
808	The value of routine non-invasive tests to predict clinical outcome in stable angina. <i>European Heart Journal</i> , 2003 , 24, 532-40	9.5	34
807	Venous coronary artery bypass surgery: a more than 20-year follow-up study. <i>European Heart Journal</i> , 2003 , 24, 927-36	9.5	15
806	The hemodynamic effects of compliance, bulging, and curvature in a saphenous vein coronary artery bypass graft model. 2003 , 11, 443-455		6
805	Biomechanical stress-induced signaling in smooth muscle cells: an update. 2003 , 1, 41-58		52
804	Revascularizaç�o mioc�rdica com enxerto composto de art�ria tor�cica interna esquerda em Y: an�lise de fluxo sang�neo. 2004 , 19, 1		
803	F-actin capping (CapZ) and other contractile saphenous vein smooth muscle proteins are altered by hemodynamic stress: a proteomic approach. 2004 , 3, 115-24		54

802	Endovascular exclusion of saphenous vein graft aneurysms complicating abdominal aortic aneurysm repair--a case report. 2004 , 38, 579-82		1
801	Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection. 2004 , 94, 1466-73		60
800	Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. <i>Circulation</i> , 2004 , 110, 1701-5	16.7	125
799	A 69-year-old woman with left main coronary artery disease. 2004 , 292, 2506-14		1
798	Mechanical stretch induces phosphorylation of p38-MAPK and apoptosis in human saphenous vein. 2004 , 24, 451-6		38
797	Origin of neointimal cells in autologous vein graft. 2004 , 24, 1147-9		6
796	Graft-extrinsic cells predominate in vein graft arterialization. 2004 , 24, 470-6		73
795	Vein graft neointimal hyperplasia is exacerbated by tumor necrosis factor receptor-1 signaling in graft-intrinsic cells. 2004 , 24, 2277-83		46
794	Murine model of neointimal formation and stenosis in vein grafts. 2004 , 24, 1180-5		35
793	Perivascular application of C-type natriuretic peptide attenuates neointimal hyperplasia in experimental vein grafts. 2004 , 25, 585-90		25
792	Non-viral in vivo thrombomodulin gene transfer prevents early loss of thromboresistance of grafted veins. 2004 , 26, 995-1001		9
791	The endothelin 1A receptor antagonist BSF 302146 is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts. 2004 , 127, 1317-22		46
790	Vein graft arterialization causes differential activation of mitogen-activated protein kinases. 2004 , 127, 1276-84		30
789	A bioabsorbable (polyglactin), nonrestrictive, external sheath inhibits porcine saphenous vein graft thickening. 2004 , 127, 1766-72		50
788	Possible involvement of protein kinase C activation in differentiation of human umbilical vein endothelium-derived cell into smooth muscle-like cell. 2004 , 96, 499-508		7
787	Non-invasive assessment of coronary artery bypass graft with retrospectively ECG-gated four-row multi-detector spiral computed tomography. 2004 , 14, 1353-62		51
786	Percutaneous intervention of saphenous vein grafts. 2004 , 13, 45-48		1
785	Vascular proteomics: linking proteomic and metabolomic changes. 2004 , 4, 3751-61		69

784	Insights into the pathogenesis of vein graft disease: lessons from intravascular ultrasound. 2004 , 2, 8	25
783	Secondary prevention after coronary artery bypass grafting--what do we know?. 2004 , 38, 69-74	8
782	Severe ostial saphenous vein graft disease leading to acute coronary syndromes following proximal aorto-saphenous anastomoses with the symmetry bypass connector device: is it a suture device or a "stent"?. 2004 , 43, 133-9	32
781	Clinical, angiographic, and intravascular ultrasound characteristics of early saphenous vein graft failure. 2004 , 44, 53-6	31
780	Free radical attenuation prevents thrombosis and enables photochemical inhibition of vein graft intimal hyperplasia. 2004 , 39, 843-9	13
779	Donor and recipient-transforming growth factor-beta 1 polymorphism and cardiac transplant-related coronary artery disease. 2004 , 13, 211-7	19
778	Effect of moderate pressure distention on the human saphenous vein vasomotor function. 2004 , 77, 108-14; discussion 114-5	18
777	Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. 2004 , 77, 1580-5	71
776	Diseased vein grafts express elevated inflammatory cytokine levels compared with atherosclerotic coronary arteries. 2004 , 77, 1575-9	25
775	Intimal hyperplasia and expression of transforming growth factor-beta1 in saphenous veins and internal mammary arteries before coronary artery surgery. 2004 , 78, 1312-8	33
774	Sternal preservation: a better way to treat most sternal wound complications after cardiac surgery. 2004 , 78, 1659-64	59
773	Hybrid coronary revascularization in the era of drug-eluting stents. 2004 , 78, 1861-7	49
772	Artery interposed to vein did not develop atherosclerosis and underwent atrophic remodeling in cholesterol-fed rabbits. 2004 , 177, 37-41	8
771	Upregulation of lectinlike oxidized low-density lipoprotein receptor-1 expression contributes to the vein graft atherosclerosis: modulation by losartan. 2004 , 177, 263-8	16
770	Statin initiation following coronary artery bypass grafting: outcome of a hospital discharge protocol. 2005 , 127, 455-63	16
769	Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. 2005 , 294, 2446-54	442
768	One-year clinical outcomes after complete arterial coronary revascularization. <i>Journal of Interventional Cardiology</i> , 2005 , 18, 437-40	1.8 2
767	Calcium and the replication of human vascular smooth muscle cells: studies on the activation and translocation of extracellular signal regulated kinase (ERK) and cyclin D1 expression. 2005 , 509, 21-30	18

766	Preprocedural white blood cell count and major adverse cardiac events late after percutaneous coronary intervention in saphenous vein grafts. 2005 , 96, 515-8	8
765	Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. 2005 , 96, 1254-9	89
764	Influence of ischemic injury on vein graft remodeling: role of cyclic adenosine monophosphate second messenger pathway in enhanced vein graft preservation. 2005 , 129, 129-37	17
763	Mild preoperative renal dysfunction as a predictor of long-term clinical outcome after coronary bypass surgery. 2005 , 129, 330-5	41
762	A Gbetagamma inhibitor reduces intimal hyperplasia in aortocoronary saphenous vein grafts. 2005 , 130, 1683-90	7
761	The role of tissue factor and P-selectin in the procoagulant response that occurs in the first month after on-pump and off-pump coronary artery bypass grafting. 2005 , 130, 1561-6	24
760	PDGF-BB induces vascular smooth muscle cell expression of high molecular weight FGF-2, which accumulates in the nucleus. 2005 , 95, 1292-300	17
759	Model of murine interpositional vein grafting. 2005 , 25, 209-12	1
758	Poor long-term patient and graft survival after primary percutaneous coronary intervention for acute myocardial infarction due to saphenous vein graft occlusion. 2005 , 65, 504-9	24
757	Early clinical results of St. Jude Medical Symmetry aortic connector. 2005 , 8, 95-9	4
756	The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. 2005 , 6, 15	28
755	Two Distinct Phenotypes of Rat Vascular Smooth Muscle Cells: Growth Rate and Production of Tumor Necrosis Factor- α . 2005 , 71, 546-551	1
754	Activation of vascular smooth muscle cells by TNF and PDGF: overlapping and complementary signal transduction mechanisms. 2005 , 65, 674-82	50
753	Cells, cytokines and cellular immunity in the pathogenesis of fibroproliferative vasculopathies. 2005 , 83, 701-15	21
752	TNF-alpha induces proliferation or apoptosis in human saphenous vein smooth muscle cells depending on phenotype. 2005 , 288, H293-301	29
751	The pathobiology of endothelin-1 in vein graft disease: are ETA receptor antagonists the solution to prevent vein graft failure?. 2005 , 3, 315-23	5
750	Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts. 2005 , 27, 302-6	24
749	Evaluation of Saphenous Vein Coronary Artery Bypass Graft Flow by Cardiovascular Magnetic Resonance. 2005 , 7, 631-637	7

748	Directed migration of smooth muscle cells to engineer plaque-resistant vein grafts. 2005 , 12, 667-75		4
747	Peri-procedural myocardial injury: 2005 update. <i>European Heart Journal</i> , 2005 , 26, 2493-519	9.5	243
746	Suppression of ICAM-1 in human venous endothelial cells by small interfering RNAs. 2005 , 28, 816-20		18
745	Coronary artery bypass grafts: assessment with multidetector CT in the early and late postoperative settings. 2005 , 25, 881-96		67
744	Biomechanical stress induces IL-6 expression in smooth muscle cells via Ras/Rac1-p38 MAPK-NF-kappaB signaling pathways. 2005 , 288, H2946-54		106
743	A Pictorial Review of Coronary Artery Bypass Grafts at Multidetector Row CT. 2005 , 127, 1371-1377		1
742	Bleeding in cardiac surgery: its prevention and treatment--an evidence-based review. 2005 , 21, 589-610		64
741	Increased connexin43 expression in human saphenous veins in culture is associated with intimal hyperplasia. 2005 , 41, 1043-52		26
740	Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. 2005 , 42, 757-64		45
739	Interventional cardiovascular pharmacotherapy: current issues. 2005 , 5, 93-102		2
738	A novel mouse model of autologous venous graft intimal hyperplasia. 2005 , 126, 106-13		14
737	Cardiovascular tissue engineering: state of the art. 2005 , 53, 599-612		79
736	Respiratory dependent compression of a venous bypass: therapy by stenting. 2005 , 80, 1904-7		1
735	Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery. 2005 , 80, 768-79		54
734	Disruption of graft endothelium correlates with early failure after off-pump coronary artery bypass surgery. 2005 , 79, 1991-8		53
733	Effects of resveratrol in storage solution on adhesion molecule expression and nitric oxide synthesis in vein grafts. 2005 , 80, 1773-8		12
732	Meta-analysis of randomized trials comparing off-pump with on-pump coronary artery bypass graft patency. 2005 , 80, 2121-5		82
731	The PProject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics. <i>American Heart Journal</i> , 2005 , 150, 643-9	4.9	45

730	Incidence and clinical correlates of ruptured plaques in saphenous vein grafts: an intravascular ultrasound study. 2005 , 45, 1974-9		27
729	A new anatomic score for prognosis after cardiac catheterization in patients with previous bypass surgery. 2005 , 46, 1684-92		39
728	The contracting and relaxing responses of human internal mammary artery grafts harvested by two different methods. 2005 , 51, 567-73		5
727	Vascular access in hemodialysis: issues, management, and emerging concepts. 2005 , 23, 249-73		73
726	Pressure distention compared with pharmacologic relaxation in vein grafting upregulates matrix metalloproteinase-2 and -9. 2005 , 42, 747-56		34
725	Long-term inhibition of Rho kinase suppresses intimal thickening in autologous vein grafts in rabbits. 2006 , 43, 1249-56		29
724	Short-term dexamethasone treatment inhibits vein graft thickening in hypercholesterolemic ApoE3Leiden transgenic mice. 2006 , 43, 809-15		23
723	Engineering of blood vessels from acellular collagen matrices coated with human endothelial cells. 2006 , 12, 2355-65		140
722	Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. 2006 , 189, 83-90		139
721	17Beta-estradiol effects on human coronaries and grafts employed in myocardial revascularization: a preliminary study. 2006 , 1, 46		2
720	Inhibition of adhesion molecule expression on human venous endothelial cells by non-viral siRNA transfection. 2006 , 10, 880-889		78
719	Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. 2006 , 17, 1112-27		427
718	Mechanisms of lumen narrowing of saphenous vein bypass grafts 12 months after implantation: an intravascular ultrasound study. <i>American Heart Journal</i> , 2006 , 151, 726-9	4.9	21
717	Distal protection in cardiovascular medicine: current status. <i>American Heart Journal</i> , 2006 , 152, 207-16	4.9	6
716	Prebypass histological and ultrastructural evaluation of the long saphenous vein as a predictor of early graft failure. 2006 , 15, 336-46		11
715	Late outcomes after intervention of vein grafts in diabetics with abciximab use. 2006 , 111, 136-41		3
714	Perivenous application of fibrin glue as external support enhanced adventitial adenovirus transfection in rabbit model. 2006 , 135, 312-6		17
713	Inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model. 2006 , 41, 431-40		43

712	Functional assessment of coronary grafts on dobutamine pharmacological stress echocardiogram. <i>Arquivos Brasileiros De Cardiologia</i> , 2006 , 87, 451-5	1.2	2
711	Perivenous application of fibrin glue prevents the early injury of jugular vein graft to arterial circulation in rabbits. 2006 , 119, 300-304		2
710	Direct comparison of relaxation and cGMP production in human coronary by-pass grafts in response to stimulation with natriuretic peptides and a nitric oxide donor. 2006 , 111, 225-31		3
709	Thermal preconditioning protects the human internal mammary artery from hypoxia/re-oxygenation-induced damage. 2006 , 33, 584-90		4
708	Coronary artery bypass grafts: assessment of graft patency and native coronary artery lesions using 16-slice MDCT. 2006 , 16, 2512-20		21
707	[The importance of cholesterol-lowering in patients after coronary artery bypass surgery]. 2006 , 95 Suppl 1, i78-82		1
706	Murine models of myocardial and limb ischemia: diagnostic end-points and relevance to clinical problems. 2006 , 45, 281-301		41
705	Comparison of ruptured plaques in native coronary arteries and in saphenous vein grafts: an intravascular ultrasound study. 2006 , 97, 593-7		9
704	Vascular-wall remodeling of 3 human bypass vessels: organ culture and smooth muscle cell properties. 2006 , 131, 651-8		24
703	Pharmacologic inhibition of vein graft neointimal hyperplasia. 2006 , 131, 1065-72		37
702	Pharmacologic relaxation of vein grafts is beneficial compared with pressure distention caused by upregulation of endothelial nitric oxide synthase and nitric oxide production. 2006 , 132, 925-32		5
701	Present status of outcome prediction of invasive coronary treatment by using genetic markers. 2006 , 27, 307-22		
700	New therapeutic possibilities for vein graft disease in the post-edifoligide era. 2006 , 2, 493-501		8
699	Gene therapy of fibroproliferative vasculopathies: current ideas in molecular mechanisms and biomedical technology. 2006 , 7, 1185-98		8
698	Systemic oxidative stress associated with lung resection during single lung ventilation. 2006 , 30, 568-9; author reply 569-70		2
697	Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. 2006 , 26, 2063-9		113
696	Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. 2006 , 29, 190-5		69
695	Reply to Schachner. 2006 , 30, 568-568		

694	Differential, time-dependent effects of perivenous application of fibrin glue on medial thickening in porcine saphenous vein grafts. 2006 , 29, 742-6; discussion 747	14
693	In vivo (animal) models of vein graft disease. 2006 , 30, 451-63	38
692	Arterial Grafting for Coronary Artery Bypass Surgery. 2006 ,	3
691	Remodeling of vein grafts after local application of fibrin glue. 2006 , 30, 567-8; author reply 568	
690	Interaction between mild hypercholesterolemia, HDL-cholesterol levels, and angiotensin II in intimal hyperplasia in mice. 2006 , 47, 476-83	10
689	Molecular signatures determining coronary artery and saphenous vein smooth muscle cell phenotypes: distinct responses to stimuli. 2006 , 26, 1058-65	55
688	Accelerated arteriosclerosis of vein grafts in inducible NO synthase(-/-) mice is related to decreased endothelial progenitor cell repair. 2006 , 98, 412-20	34
687	Anti-proliferative and anti-inflammatory effects of topical MAPK inhibition in arterialized vein grafts. 2006 , 20, 398-400	22
686	The effect of phenotype on mechanical stretch-induced vascular smooth muscle cell apoptosis. 2006 , 43, 229-37	29
685	Novel faces to old friends: a central role of inducible NO synthase for progenitor cell recruitment and a new antiinflammatory mechanisms of statins. 2006 , 98, 303-5	4
684	Extracellular superoxide dismutase with vaccinia virus anti-inflammatory protein 35K or tissue inhibitor of metalloproteinase-1: Combination gene therapy in the treatment of vein graft stenosis in rabbits. 2006 , 17, 405-14	19
683	Biomechanical considerations in the design of graft: the homeostasis hypothesis. 2006 , 8, 499-535	66
682	Regulation of smooth muscle cells in development and vascular disease: current therapeutic strategies. 2006 , 4, 789-800	41
681	Short- and long-term effects of cytochalasin D, paclitaxel and rapamycin on wall thickening in experimental porcine vein grafts. 2007 , 73, 607-17	28
680	The dynamic vasa vasorum. 2007 , 75, 649-58	161
679	Vascular bed origin dictates flow pattern regulation of endothelial adhesion molecule expression. 2007 , 292, H2167-75	54
678	Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor. 2007 , 3, 43-55	10
677	Release of TNF-alpha during stent implantation into saphenous vein aortocoronary bypass grafts and its relation to plaque extrusion and restenosis. 2007 , 292, H2295-9	31

676	Emerging role of IGF-1R in stretch-induced neointimal hyperplasia in venous grafts. 2007 , 27, 1679-81	5
675	Paclitaxel treatment reduces neointimal hyperplasia in cultured human saphenous veins. 2007 , 32, 906-11	12
674	Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. 2007 , 104, 12988-93	37
673	Diagnostic performance of 64-slice computed tomography in evaluation of coronary artery bypass grafts. 2007 , 189, 574-80	56
672	Time from coronary artery bypass surgery does not affect outcome in patients treated with primary angioplasty for acute saphenous vein graft occlusion. 2007 , 93, 381-2	
671	Controlled release of basic fibroblast growth factor from gelatin hydrogel sheet improves structural and physiological properties of vein graft in rat. 2007 , 27, 548-55	21
670	Mouse strain differential neointimal response in vein grafts and wire-injured arteries. 2007 , 71, 1649-52	12
669	Impact of scanning direction on heart rate at certain levels of heart in electrocardiogram-gated 16-multidetector computed tomography angiography of coronary artery bypass grafts. 2007 , 31, 5-8	2
668	The comparison of platelet activity between patients with patent vs. occluded coronary artery bypass grafts. 2007 , 120, 523-9	3
667	Does stenosis severity of native vessels influence bypass graft patency? A prospective fractional flow reserve-guided study. 2007 , 83, 2093-7	170
666	Interactive effects of homocysteine and copper on angiogenesis in porcine isolated saphenous vein. 2007 , 84, 43-9	22
665	Characterization of porcine arterial endothelial cells cultured on amniotic membrane, a potential matrix for vascular tissue engineering. 2007 , 357, 984-90	32
664	Hypercholesterolemia contributes to the development of atherosclerosis and vascular remodeling by recruiting bone marrow-derived cells in cuff-induced vascular injury. 2007 , 363, 782-7	17
663	The role of preexisting pathology in the development of neointimal hyperplasia in coronary artery bypass grafts. 2007 , 142, 351-6	6
662	Coronary artery bypass grafting for Fabry disease: veins more suitable than arteries?. 2007 , 38, 1864-7	12
661	Possible contribution of pericardial tamponade to coronary artery bypass graft occlusion. 2007 , 115, 422-4	1
660	Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG. 2007 , 118, 164-9	18
659	CRP, IL-6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events?. 2007 , 120, 108-14	34

658	Renal dysfunction increases the risk of saphenous vein graft occlusion: results from the Post-CABG trial. 2007 , 193, 414-20	11
657	Central arterial aging and the epidemic of systolic hypertension and atherosclerosis. 2007 , 1, 302-40	28
656	Thrombosis: the last frontier of coronary stenting?. 2007 , 369, 619-21	16
655	Arterialization of a vein graft promotes cell cycle progression through Akt and p38 mitogen-activated protein kinase pathways: impact of the preparation procedure. 2007 , 23, 1147-54	7
654	Cytokines and the early vein graft: strategies to enhance durability. 2007 , 45 Suppl A, A92-8	18
653	Gene response in endothelial cells cultured on engineered surfaces is regulated by shear stress. 2007 , 13, 1607-14	23
652	Smoking cessation is associated with reduced long-term mortality and the need for repeat interventions after coronary artery bypass grafting. 2007 , 14, 448-50	17
651	Cardiac CT angiography after coronary bypass surgery: prevalence of incidental findings. 2007 , 189, 414-9	77
650	Remodeling of experimental arteriovenous fistula with increased matrix metalloproteinase expression in rats. 2007 , 45, 804-11	44
649	Blockade of monocyte chemoattractant protein-1 by adenoviral gene transfer inhibits experimental vein graft neointimal formation. 2007 , 45, 1236-43	40
648	Celiprolol reduces the intimal thickening of autogenous vein grafts via an enhancement of nitric oxide function through an inhibition of superoxide production. 2007 , 46, 116-23	16
647	Smooth muscle cells cultured from human saphenous vein exhibit increased proliferation, invasion, and mitogen-activated protein kinase activation in vitro compared with paired internal mammary artery cells. 2007 , 45, 1022-8	38
646	Urokinase-type plasminogen activator deficiency (uPA-KO) prevented carotid artery ligation-induced vascular remodeling in mice. 2007 , 149, 70-5	4
645	Flow and wall shear stress in end-to-side and side-to-side anastomosis of venous coronary artery bypass grafts. 2007 , 6, 35	28
644	Effect of external stents on prevention of intimal hyperplasia in a canine vein graft model. 2007 , 120, 2264-2267	3
643	Chronic total occlusion treatment in post-CABG patients: saphenous vein graft versus native vessel recanalization-long-term follow-up in the drug-eluting stent era. 2007 , 70, 21-5	25
642	On the biology of saphenous vein grafts fitted with external synthetic sheaths and stents. 2007 , 28, 895-908	72
641	Coculture of endothelial and smooth muscle cells on a collagen membrane in the development of a small-diameter vascular graft. 2007 , 28, 1385-92	76

640	Risk of local adverse events by gender following cardiac catheterization. 2007 , 16, 125-31		22
639	Feasibility of percutaneous coronary interventions in early postcoronary artery bypass graft occlusion or stenosis. <i>Journal of Interventional Cardiology</i> , 2007 , 20, 204-8	1.8	5
638	Clinical follow-up of paclitaxel-eluting (TAXUS) stents for the treatment of saphenous vein graft disease. <i>Journal of Interventional Cardiology</i> , 2007 , 20, 258-64	1.8	6
637	Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. <i>Journal of Interventional Cardiology</i> , 2007 , 20, 458-65	1.8	30
636	Chlamydia pneumoniae aggravates vein graft intimal hyperplasia in a rat model. 2007 , 7, 111		1
635	Inhibition of adhesion molecule expression on human venous endothelial cells by non-viral siRNA transfection. 2007 , 11, 139-47		22
634	Autonomously vascularized cellular constructs in tissue engineering: opening a new perspective for biomedical science. 2007 , 11, 6-20		68
633	Orally administered penicillamine is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts. 2007 , 133, 494-500		9
632	Patterns and predictors of statin use after coronary artery bypass graft surgery. 2007 , 134, 932-8		43
631	Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein-carotid artery interposition grafting: a comparison with aspirin and morpholinosydnonimine (SIN-1). 2007 , 134, 1033-9		15
630	Does 16-MDCT angiography scanning direction affect image quality of coronary artery bypass grafts and the native coronary arteries?. 2007 , 17, 97-102		1
629	Coronary artery bypass grafts and MDCT imaging: what to know and what to look for. 2007 , 17, 3166-78		24
628	A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial. 2008 , 1, 248-57		27
627	Tanshinone IIA from <i>Salvia miltiorrhiza</i> BUNGE inhibits human aortic smooth muscle cell migration and MMP-9 activity through AKT signaling pathway. 2008 , 104, 15-26		83
626	Development of a composite vascular scaffolding system that withstands physiological vascular conditions. 2008 , 29, 2891-8		292
625	Evaluation of graft patency by computed tomographic angiography in symptom-free post-coronary artery bypass surgery patients. 2008 , 15, 201-8		2
624	Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). 2008 , 102, 552-8		36
623	Computed tomography of coronary artery disease. 2008 , 43, 122-35		3

622	Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: results from the prospective randomized trial PRAGUE 11-Coronary Artery Bypass and REactivity of Thrombocytes (CABARET). 2008 , 136, 1054-60		39
621	Adventitial delivery of platelet-derived endothelial cell growth factor gene prevented intimal hyperplasia of vein graft. 2008 , 48, 1566-74		22
620	Accelerated intimal hyperplasia in aortocoronary internal mammary vein grafts in minipigs. 2008 , 3, 20		7
619	Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. 2008 , 51, 1938-43		72
618	Vascular Complications in Human Disease. 2008 ,		
617	Serial quantitative coronary analyses for the evaluation of one-year change in saphenous vein grafts. 2008 , 85, 525-9		1
616	Effects of cilostazol and k-134 on reconstructive surgery using prosthetic grafts in the abdominal aorta of beagle dogs. 2008 , 123, 122-9		
615	Inhibition of vein graft intimal hyperplasia by periadventitial application of hyaluronic acid-carboxymethyl cellulose: an experimental study. 2008 , 42, 161-5		7
614	Long-term engraftment of bone marrow-derived cells in the intimal hyperplasia lesion of autologous vein grafts. 2008 , 172, 839-48		24
613	Mesenchymal stem cells differentiate into an endothelial phenotype, reduce neointimal formation, and enhance endothelial function in a rat vein grafting model. 2008 , 17, 785-93		68
612	Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. <i>Circulation</i> , 2008 , 118, S65-70	16.7	47
611	Impact of statin use on outcomes after coronary artery bypass graft surgery. <i>Circulation</i> , 2008 , 118, 1785-92	16.7	92
610	Pathophysiology of aortocoronary saphenous vein bypass graft disease. 2008 , 16, 331-6		36
609	Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. <i>Circulation</i> , 2008 , 117, 790-7	16.7	113
608	Tumor necrosis factor receptor-2 signaling attenuates vein graft neointima formation by promoting endothelial recovery. 2008 , 28, 284-9		33
607	The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. <i>European Heart Journal</i> , 2008 , 29, 1057-71	9.5	121
606	Gene therapy to prevent occlusion of venous bypass grafts. 2008 , 6, 641-52		21
605	Prothrombotic gene expression profile in vascular smooth muscle cells of human saphenous vein, but not internal mammary artery. 2008 , 28, 705-10		21

604	A comparison of reactive oxygen species metabolism in the rat aorta and vena cava: focus on xanthine oxidase. 2008 , 295, H1341-H1350	11
603	Peripheral Blood Stem Cells. 2008 , 438-455	
602	Vessel graft atherosclerosis in murine models. 2008 , 9, 239-50	2
601	Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. 2008 , 34, 93-108	58
600	Metabolic syndrome predicts 10-year mortality in non-diabetic patients following coronary artery bypass surgery. 2008 , 72, 1481-6	40
599	Antiplatelet Therapy and Coronary Bypass Surgery: Risks and Benefits. 231-250	
598	Cellular Mechanisms of Bypass Vein Graft Arterialization and Approaches to Attenuate Graft Remodeling. 2008 , 5, 33-54	
597	Higher platelet activity is present in patients with restenosis after percutaneous coronary intervention compared with patients with an occlusion of coronary artery bypass graft. 2008 , 19, 807-12	1
596	. 2008 ,	1
595	Percutaneous coronary intervention in saphenous vein graft disease. 2008 , 309-318	2
594	Envejecimiento cardiovascular. 2008 , 136,	1
593	Human saphenous vein organ culture under controlled hemodynamic conditions. 2008 , 63, 683-8	16
592	Reduction of early vein graft thrombosis by tissue plasminogen activator gene transfer. 2009 , 102, 145-52	15
591	Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc, SLC3A2). 2009 , 206, 2397-406	35
590	Mechanical strain induces expression of C-reactive protein in human blood vessels. 2009 , 330, 206-11	15
589	Negative action of hepatocyte growth factor/c-Met system on angiotensin II signaling via ligand-dependent epithelial growth factor receptor degradation mechanism in vascular smooth muscle cells. 2009 , 105, 667-75, 13 p following 675	37
588	Non-invasive assessment of saphenous vein graft patency in asymptomatic patients. 2009 , 82, 291-5	13
587	Plasma ADMA predicts restenosis of arteriovenous fistula. 2009 , 20, 213-22	31

586	Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients. 2009 , 297, C1307-17	45
585	Everolimus attenuates neointimal hyperplasia in cultured human saphenous vein grafts. 2009 , 35, 515-20	7
584	Which is the best statin for the postoperative coronary artery bypass graft patient?. 2009 , 36, 628-32	3
583	Protective role of clusterin/apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. 2009 , 29, 1558-64	58
582	Coronary artery bypass grafting with Y-saphenous vein grafts. 2009 , 60, 668-75	7
581	Risk factors for lower-extremity vein graft failure. 2009 , 22, 216-26	26
580	Revision of vein bypass grafts: factors affecting durability of interventions. 2009 , 22, 261-6	8
579	N-acetylcysteine prevents neointima formation in experimental venous bypass grafts. 2009 , 96, 941-50	10
578	Electrospun polylactide/silk fibroin/gelatin composite tubular scaffolds for small-diameter tissue engineering blood vessels. 2009 , 113, 2675-2682	51
577	Extravascular perivenous fibrin support leads to aneurysmal degeneration and intimal hyperplasia in arterialized vein grafts in the rat. 2009 , 394, 357-62	3
576	Therapeutisches Potenzial der Stickstoffmonoxid-Synthase-Isoformen in Restenose, Transplantat- und Bypassarteriosklerose. 2009 , 14, 108-117	
575	Adenovirus-mediated gene transfer of fibromodulin inhibits neointimal hyperplasia in an organ culture model of human saphenous vein graft disease. 2009 , 16, 1154-62	24
574	Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial. 2009 , 2, 855-60	35
573	Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety. 2009 , 8, 559-71	54
572	Papel de los productos de glicosilaci3n avanzada en la supresi3n inducida por aminoguanidina en un modelo de hiperplasia intimal venosa en ratas diab3ticas. 2009 , 23, 270-279	
571	Current role of emboli protection devices in percutaneous coronary and vascular interventions. <i>American Heart Journal</i> , 2009 , 157, 263-70	4.9 14
570	Saphenous vein conduits harvested by endoscopic technique exhibit structural and functional damage. 2009 , 87, 62-70	100
569	Differential effects of natriuretic peptides on arterial and venous coronary artery bypass conduits. 2009 , 87, 748-56	8

568	Sarpogrelate hydrochloride reduced intimal hyperplasia in experimental rabbit vein graft. 2009 , 49, 1272-81	27
567	Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemic apolipoprotein E3-Leiden mice. 2009 , 50, 152-60	34
566	Healing Characteristics and Complications of Prosthetic and Biological Vascular Grafts. 2009 , 665-687	1
565	Integrating Cardiology for Nuclear Medicine Physicians. 2009 ,	1
564	Low wall shear stress predicts subsequent development of wall hypertrophy in lower limb bypass grafts. 2009 , 3, 32-38	24
563	Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting. 2009 , 88, 59-62	57
562	Coronary vein graft disease: pathogenesis and prevention. 2009 , 25, e57-62	128
561	Rôle du récepteur RAGE sur l'inhibition de l'hyperplasie myointimale veineuse induite par l'aminoguanidine chez le rat diabétique. 2009 , 23, 265-273	
560	The role of RAGE in aminoguanidine-induced suppression of venous intimal hyperplasia in diabetic rats. 2009 , 23, 246-54	1
559	Low-dose spironolactone: effects on artery-to-artery vein grafts and percutaneous coronary intervention sites. 2009 , 16, 204-14	4
558	C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target. 2010 , 16, 4080-8	57
557	Animal models for studying neointima formation. 2010 , 8, 198-219	16
556	Role of nuclear factor kappaB in cardiovascular health and disease. 2010 , 118, 593-605	183
555	Influence of dynamic training on hemodynamic, neurohormonal responses to static exercise and on inflammatory markers in patients after coronary artery bypass grafting. 2010 , 74, 2598-604	22
554	Folic acid administration reduces neointimal thickening, augments neo-vasa vasorum formation and reduces oxidative stress in saphenous vein grafts from pigs used as a model of diabetes. 2010 , 53, 980-8	11
553	Virtual histology by intravascular ultrasound study on degenerative aortocoronary saphenous vein grafts. 2010 , 25, 175-81	11
552	Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program. 2010 , 3, 742-50	11
551	Mid-term follow-up after retrograde recanalization of chronically occluded saphenous vein graft. 2010 , 99, 257-9	1

550	Multifunctional nanocomplexes for gene transfer and gene therapy. 2010 , 26, 69-81		61
549	Association of low serum fetuin A levels with poor arteriovenous access patency in patients undergoing maintenance hemodialysis. 2010 , 56, 720-7		18
548	Long term performance of small-diameter vascular grafts made of a poly(ether)urethane-polydimethylsiloxane semi-interpenetrating polymeric network. 2010 , 31, 2592-605		88
547	. 2010 ,		3
546	Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. <i>Circulation</i> , 2010 , 122, 2680-7	16.7	149
545	Human umbilical cord blood-derived endothelial cells reendothelialize vein grafts and prevent thrombosis. 2010 , 30, 2150-5		27
544	Inhibition of neointimal formation and hyperplasia in vein grafts by external stent/sheath. 2010 , 15, 287-97		39
543	Effect of matrix metalloproteinase-9 knockout on vein graft remodelling in mice. 2010 , 47, 299-308		26
542	Stenting of complex lesions: an overview. 2010 , 7, 485-96		37
541	Coronary Anatomy for Surgeons. 2010 , 179-199		1
540	Development of viral vectors for use in cardiovascular gene therapy. 2010 , 2, 334-71		28
539	A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. 2010 , 88, 367-75		18
538	Pericytes in the macrovascular intima: possible physiological and pathogenetic impact. 2010 , 298, H754-70		38
537	Role of multidetector CT in the evaluation of coronary artery bypass grafts. 2010 , 2, 77-86		2
536	In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1.ATF), a cell-surface directed matrix metalloproteinase inhibitor. 2010 , 51, 429-37		16
535	Successful treatment of saphenous venous graft thrombus by tirofiban infusion. 2010 , 39, 237-9		3
534	Gene transfer of COX-1 improves lumen size and blood flow in carotid bypass grafts. 2010 , 161, 162-7		6
533	Biomechanical stress induces novel arterial intima-enriched genes: implications for vascular adaptation to stress. 2010 , 19, e13-20		19

532	Association of prior coronary artery bypass graft surgery with quality of care of patients with non-ST-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines. <i>American Heart Journal</i> , 2010 , 160, 951-7	4.9	24
531	Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. <i>American Heart Journal</i> , 2010 , 160, 1178-84	4.9	78
530	Proteomic analysis of plasma from patients undergoing coronary artery bypass grafting reveals a protease/antiprotease imbalance in favor of the serpin alpha1-antichymotrypsin. 2010 , 9, 2347-57		14
529	Evaluation of bypass grafts and stents. 2010 , 48, 757-70		6
528	Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering. 2010 , 16, 467-91		253
527	Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. 2011 , 57, 1069-77		67
526	Endothelin-1 (ET-1) and vein graft failure and the therapeutic potential of ET-1 receptor antagonists. 2011 , 63, 483-9		12
525	Vascular anastomosis using controlled phase transitions in poloxamer gels. 2011 , 17, 1147-52		67
524	Inhibition of transforming growth factor- β restores endothelial thromboresistance in vein grafts. 2011 , 54, 1117-1123.e1		10
523	Pioglitazone prevents intimal hyperplasia in experimental rabbit vein grafts. 2011 , 54, 1753-9		5
522	Topical HDL administration reduces vein graft atherosclerosis in apo E deficient mice. 2011 , 214, 271-8		24
521	Peripheral Blood Stem Cells. 2011 , 383-401		
520	Assessment of Coronary Artery Bypass Graft (CABG) Patency and Graft Disease Using Multidetector Computed Tomography (MDCT). 2011 ,		1
519	Biomaterials and the Microvasculature. 2011 , 35-50		
518	Massive thrombosis of venous aortic coronary bypass graft treated with bivalirudin and combined technique of thrombectomy and filter distal protection. 2011 , 12, 601-4		
517	Lipid-lowering therapy and coronary artery bypass graft surgery: what are the benefits?. 2011 , 26, 508-17		27
516	A novel approach to aortocoronary saphenous venous graft percutaneous treatment. 2011 , 3, 309-313		
515	Chemokine receptor CCR5: from AIDS to atherosclerosis. 2011 , 162, 1453-69		120

514	Quantification of thermal spread and burst pressure after endoscopic vessel harvesting: a comparison of 2 commercially available devices. 2011 , 142, 203-8	9
513	Recombinant factor VIIa affects anastomotic patency of vascular grafts in a rabbit model. 2011 , 142, 418-23	
512	Myocardial revascularization by coronary arterial bypass graft: past, present, and future. <i>Current Problems in Cardiology</i> , 2011 , 36, 325-68	17.1 8
511	Impact of the learning curve for endoscopic vein harvest on conduit quality and early graft patency. 2011 , 91, 1385-91; discussion 1391-2	49
510	Protandim attenuates intimal hyperplasia in human saphenous veins cultured ex vivo via a catalase-dependent pathway. 2011 , 50, 700-9	18
509	Redox regulation of human protease-activated receptor-2 by activated factor X. 2011 , 51, 1758-64	13
508	Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial. 2011 , 92, 1284-90; discussion 1290-1	62
507	Expression of apolipoprotein A-I in rabbit carotid endothelium protects against atherosclerosis. 2011 , 19, 1833-41	29
506	Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. 2011 , 32, 378-85	10
505	Arterial pOB stimulates intimal hyperplasia and serum stimulates inward eutrophic remodeling in porcine saphenous veins cultured ex vivo. 2011 , 10, 161-75	4
504	Pulsatile ex vivo perfusion of human saphenous vein grafts under controlled pressure conditions increases MMP-2 expression. 2011 , 10, 62	11
503	PDGF-induced proliferation in human arterial and venous smooth muscle cells: molecular basis for differential effects of PDGF isoforms. 2011 , 112, 289-98	49
502	Safety and efficacy of drug eluting stents compared with bare metal stents for saphenous vein graft interventions: a comprehensive meta-analysis of randomized trials and observational studies comprising 7,994 patients. 2011 , 77, 343-55	36
501	Outcomes of patients with acute myocardial infarction from a saphenous vein graft culprit undergoing percutaneous coronary intervention. 2011 , 78, 23-9	18
500	Evaluation of culprit saphenous vein graft lesions with optical coherence tomography in patients with acute coronary syndromes. 2011 , 4, 683-93	20
499	Multifaceted role of plasminogen activator inhibitor-1 in regulating early remodeling of vein bypass grafts. 2011 , 31, 1781-7	31
498	Effective silencing of adhesion molecules on venous endothelial cells for protection of venous bypass grafts. 2011 , 40, 1241-7	3
497	Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. 2011 , 31, 95-101	60

496	Highly flexible nitinol mesh to encase aortocoronary saphenous vein grafts: first clinical experiences and angiographic results nine months postoperatively. 2011 , 13, 396-400		33
495	A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts. 2011 , 25, 4253-63		176
494	Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. <i>Circulation</i> , 2011 , 124, S135-42	16.7	52
493	Current debate on the role of embolic protection devices. 2012 , 46, 441-6		1
492	Effect of oxidized low-density lipoprotein concentration polarization on human smooth muscle cells proliferation, cycle, apoptosis and oxidized low-density lipoprotein uptake. 2012 , 9, 1233-40		17
491	The impact of distension pressure on acute endothelial cell loss and neointimal proliferation in saphenous vein grafts. 2012 , 42, e74-9		21
490	Use of Microvena Snare Catheter in Non-ST Elevation Myocardial Infarction Due to Saphenous Vein Graft Occlusive Thrombi. 2012 , 13, 19-21		1
489	Targeted Treatments for Restenosis and Vein Graft Disease. 2012 , 2012, 1-23		1
488	Role of osteopontin in the development of neointimal hyperplasia in vein grafts. 2012 , 41, 1384-9		14
487	Histopathologic insight into saphenous vein bypass graft disease. 2012 , 123, 208-15		8
486	Embollic protection devices in saphenous vein graft and native vessel percutaneous intervention: a review. 2012 , 8, 192-9		8
485	Training a sophisticated microsurgical technique: interposition of external jugular vein graft in the common carotid artery in rats. 2012 ,		3
484	A novel function of FoxO transcription factors in thrombin-stimulated vascular smooth muscle cell proliferation. 2012 , 108, 148-58		18
483	Percutaneous coronary intervention in patients with prior coronary bypass surgery in 2012. 2012 , 4, 111-124		
482	Evaluation of aspirin effect on platelet function early after coronary artery bypass grafting. 2012 , 26, 575-80		12
481	Use of aspirin and clopidogrel after coronary artery bypass graft surgery. 2012 , 46, 678-87		23
480	Differences in angiotensin convertase enzyme (ACE) activity and expression may contribute to shorter event free period after coronary artery bypass graft surgery. 2012 , 30, 136-44		1
479	C1-esterase inhibitor protects against early vein graft remodeling under arterial blood pressure. 2012 , 220, 86-92		9

478	Statin therapy prevents expansive remodeling in venous bypass grafts. 2012 , 223, 106-13	15
477	Diagnostic accuracy of 64-slice multidetector computed tomography in evaluation of post-coronary artery bypass grafts in correlation with invasive coronary angiography. 2012 , 64, 254-60	5
476	The use of antithrombotic therapies in reducing synthetic small-diameter vascular graft thrombosis. 2012 , 46, 212-22	32
475	Local delivery of pravastatin inhibits intimal formation in a mouse vein graft model. 2012 , 28, 750-7	12
474	FSP-1 silencing in bone marrow cells suppresses neointima formation in vein graft. 2012 , 110, 230-40	34
473	Characteristics of the actions by which 5-hydroxytryptamine affects electrical and mechanical activities in rabbit jugular vein graft. 2012 , 166, 1419-32	7
472	Preexisting venous calcification prior to dialysis vascular access surgery. 2012 , 25, 592-5	25
471	Pathophysiology of saphenous vein graft failure: a brief overview of interventions. 2012 , 12, 114-20	41
470	Animal models for studying vein graft failure and therapeutic interventions. 2012 , 12, 121-6	18
469	Oxidative stress and vein graft failure: a focus on NADH oxidase, nitric oxide and eicosanoids. 2012 , 12, 160-5	24
468	Statins and vein graft failure in coronary bypass surgery. 2012 , 12, 172-80	17
467	Pharmacological strategies aimed at reducing complications associated with coronary artery bypass graft surgery. 2012 , 12, 111-3	2
466	Oversized vein grafts develop advanced atherosclerosis in hypercholesterolemic minipigs. 2012 , 12, 24	4
465	Utility of nuclear stress imaging for detecting coronary artery bypass graft disease. 2012 , 12, 62	9
464	Influence of ischemia before vein grafting on early hyperplasia of the graft and the dynamic changes of the intima after grafting. 2012 , 7, 90	1
463	Ezetimibe reduces intimal hyperplasia in rabbit jugular vein graft. 2012 , 56, 1689-97	6
462	Edifoligide and long-term outcomes after coronary artery bypass grafting: PProject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. <i>American Heart Journal</i> , 2012 , 164, 379-386.e1	4-9 33
461	Pathology of drug-eluting versus bare-metal stents in saphenous vein bypass graft lesions. 2012 , 5, 666-74	41

460	Prevention of coronary in-stent restenosis and vein graft failure: does vascular gene therapy have a role?. 2012 , 136, 23-34		22
459	Evaluation of Bypass Grafts. 2012 , 153-163		
458	Under-prescribing and non-adherence to medications after coronary bypass surgery in older adults: strategies to improve adherence. 2012 , 29, 93-103		21
457	Intrapulmonary shear stress enhancement: a new therapeutic approach in pulmonary arterial hypertension. 2012 , 33, 1332-42		6
456	Plaque rupture complications in murine atherosclerotic vein grafts can be prevented by TIMP-1 overexpression. 2012 , 7, e47134		32
455	Mid-term outcomes of total arterial revascularization versus conventional coronary surgery in isolated three-vessel coronary disease. 2012 , 27, 1051-6		2
454	Should right coronary bypass grafts be anastomosed proximal or distal to the crux? A comparison of graft patencies. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2012 , 18, 331-7	1.8	2
453	Histological evaluation of age-related variations in saphenous vein grafts used for coronary artery bypass grafting. 2012 , 8, 1041-7		8
452	Differential effects of substrate modulus on human vascular endothelial, smooth muscle, and fibroblastic cells. 2012 , 100, 1356-67		42
451	Vein graft failure: current clinical practice and potential for gene therapeutics. 2012 , 19, 630-6		33
450	Genetic causation of neointimal hyperplasia in hemodialysis vascular access dysfunction. 2012 , 25, 65-73		9
449	A perivascular system releasing sirolimus prevented intimal hyperplasia in a rabbit model in a medium-term study. 2012 , 427, 311-9		18
448	High-pressure distention of the saphenous vein during preparation results in increased markers of inflammation: a potential mechanism for graft failure. 2012 , 93, 552-8		49
447	Computed tomography angiography of coronary artery bypass graft grafts. 2012 , 47, 240-52		1
446	Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. 2012 , 56, 47-55		24
445	Does high-density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: exploratory analysis from the CASCADE trial. 2013 , 8, 172		9
444	Expandable external support device to improve Saphenous Vein Graft Patency after CABG. 2013 , 8, 122		28
443	Gene therapy for cardiovascular disease: perspectives and potential. 2013 , 58, 174-81		21

442	Inflammatory Response in Cardiovascular Surgery. 2013 ,		2
441	Long-term clinical outcome after fractional flow reserve- versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts. <i>American Heart Journal</i> , 2013 , 166, 110-8	4-9	41
440	Anaortic, off-pump coronary artery surgery: should it be the standard-of-care?. 2013 , 5, 221-230		1
439	Cyclic adenosine monophosphate response-element binding protein activation by mitogen-activated protein kinase-activated protein kinase 3 and four-and-a-half LIM domains 5 plays a key role for vein graft intimal hyperplasia. 2013 , 57, 182-93, 193.e1-10		11
438	Effects of irradiated biodegradable polymer in endothelial cell monolayer formation. 2013 , 314, 86-89		1
437	Immediate stent recoil in an anastomotic vein graft lesion treated by cutting balloon angioplasty. 2013 , 32, 935-939		3
436	Immediate stent recoil in an anastomotic vein graft lesion treated by cutting balloon angioplasty. 2013 , 32, 935-9		3
435	Cascade plasma filtration during the first year after CABG in patients with hyperlipidemia refractory to statins. 2013 , 14, 101-5		2
434	Is reconstruction of the left anterior descending artery with saphenous vein patching equal to onlay patch reconstruction using the left internal thoracic artery?. 2013 , 145, 616-7		
433	Gene therapy for the prevention of vein graft disease. 2013 , 161, 321-38		17
432	Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials. 2013 , 35, 1125-36		15
431	Bone morphogenic protein-4 contributes to venous endothelial dysfunction in patients with diabetes undergoing coronary revascularization. 2013 , 95, 1331-9		13
430	Prehospitalization antiplatelet therapy and outcomes after saphenous vein graft intervention. 2013 , 111, 153-8		4
429	Prevalence and outcomes of intermediate saphenous vein graft lesions: findings from the stenting of saphenous vein grafts randomized-controlled trial. 2013 , 168, 2468-73		16
428	The accelerated atherogenesis of venous grafts might be attributed to aggravated concentration polarization of low density lipoproteins: a numerical study. 2013 , 46, 2388-93		1
427	Percutaneous coronary intervention in patients with previous coronary artery bypass grafting (from the j-Cypher Registry). 2013 , 112, 1110-9		4
426	Pathology of Saphenous Vein Grafts. 2013 , 2, 241-249		4
425	Small interfering RNA targeting nuclear factor kappa B to prevent vein graft stenosis in rat models. 2013 , 45, 2553-8		9

424	Red blood cell distribution width in saphenous vein graft disease. 2013 , 29, 448-51		11
423	p38 MAPK inhibitor, CBS3830 limits vascular remodelling in arterialised vein grafts. 2013 , 22, 751-8		12
422	Saphenous vein graft failure and clinical outcomes: toward a surrogate end point in patients following coronary artery bypass surgery?. <i>American Heart Journal</i> , 2013 , 165, 639-43	4-9	33
421	Intimal thickness associated with endothelial dysfunction in human vein grafts. 2013 , 180, e55-62		22
420	Comparison of outcomes of patients with ST-segment elevation myocardial infarction with versus without previous coronary artery bypass grafting (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). 2013 , 111, 1377-86		18
419	Degenerated Saphenous Vein Graft Intervention: Should We Target the Native Vessel instead?. 2013 , 2, 323-337		2
418	Invited commentary. 2013 , 95, 1339		
417	Comparison of procedural success and long-term outcomes of stent thrombosis in coronary bypass grafts versus native coronary arteries. 2013 , 111, 689-94		
416	Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. <i>Journal of Cardiac Surgery</i> , 2013 , 28, 109-16	1-3	108
415	Peripheral Blood Stem Cells. 2013 , 573-586		1
414	Optimal Stenting in Saphenous Vein Graft Intervention. 2013 , 2, 307-313		
413	Management of Complications During Saphenous Vein Graft Interventions. 2013 , 2, 339-346		
412	Natural History of Saphenous Vein Grafts. 2013 , 2, 251-258		3
411	The role of multidetector computed tomography coronary angiography in imaging complications post-cardiac surgery. 2013 , 68, e254-65		4
410	Coronary artery bypass grafting: Part 1--the evolution over the first 50 years. <i>European Heart Journal</i> , 2013 , 34, 2862-72	9-5	90
409	Anaortic, total-arterial, off-pump coronary artery bypass surgery: why bother?. 2013 , 22, 161-70		12
408	Preexisting high expression of matrix metalloproteinase-2 in tunica media of saphenous vein conduits is associated with unfavorable long-term outcomes after coronary artery bypass grafting. 2013 , 2013, 730721		12
407	Saphenous vein graft disease: review of pathophysiology, prevention, and treatment. 2013 , 21, 101-9		47

406	Intraoperative transit-time flow measurement is not altered in venous bypass grafts covered by the eSVS mesh. 2013 , 8, 37-41		4
405	miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation. <i>European Heart Journal</i> , 2013 , 34, 1636-43	9.5	50
404	Correlates of saphenous vein graft hyperplasia and occlusion 1 year after coronary artery bypass grafting: analysis from the CASCADE randomized trial. <i>Circulation</i> , 2013 , 128, S213-8	16.7	49
403	Glucocorticoids in adult cardiac surgery; old drugs revisited. 2013 , 28, 395-402		4
402	Aspirate from human stented native coronary arteries vs. saphenous vein grafts: more endothelin but less particulate debris. 2013 , 305, H1222-9		22
401	Gene therapy for vein graft failure. <i>Journal of Cardiac Surgery</i> , 2013 , 28, 144-7	1.3	9
400	Inhibition of neointimal hyperplasia in a rabbit vein graft model following non-viral transfection with human iNOS cDNA. 2013 , 20, 979-86		18
399	5-hydroxytryptamine receptors as targets for drug therapies of vascular-related diseases. 2013 , 36, 1410-5		14
398	Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions. 2013 , 257, 824-33		219
397	Suturless Microvascular Anastomosis with the Aid of Heparin Loaded Poloxamer 407. 2013 , 132, 143-144		
396	Predictive factors of late venous aortocoronary graft failure: ultrastructural studies. 2013 , 8, e70628		20
395	Treatment of Coronary Artery Bypass Graft Failure. 2013 ,		3
394	Multidetector CT Imaging of Coronary Artery Stent and Coronary Artery Bypass Graft. 2013 ,		
393	Impact of Renal Dysfunction and Peripheral Arterial Disease on Post-Operative Outcomes After Coronary Artery Bypass Grafting. 2013 ,		1
392	THE ROLE OF LIPOTROPIC THERAPY IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE BEFORE AND AFTER CORONARY REVASCULARIZATION. 2013 , 9, 564-569		
391	Computerized tomographic angiography in patients having eSVS Mesh(R) supported coronary saphenous vein grafts: intermediate term results. 2014 , 9, 138		6
390	Current trends in surgical revascularization of multivessel coronary artery disease with arterial grafts. 2014 , 55, 381-5		9
389	Relationship between late arteriovenous fistula (AVF) stenosis and neutrophil-lymphocyte ratio (NLR) in chronic hemodialysis patients. 2014 , 36, 1390-4		25

388	Safety and efficacy outcomes of preoperative aspirin in patients undergoing coronary artery bypass grafting: a systematic review and meta-analysis. 2014 , 19, 97-113	20
387	Beta-thromboglobulin as a marker of perioperative myocardial infarction in patients undergoing coronary artery bypass grafting following aspirin discontinuation. 2014 , 25, 603-7	3
386	C-reactive protein induces expression of tissue factor and plasminogen activator inhibitor-1 and promotes fibrin accumulation in vein grafts. 2014 , 12, 1667-77	16
385	Percutaneous coronary intervention for acute coronary syndrome due to graft failure: use of bare-metal and drug-eluting stents and subsequent long-term clinical outcome. 2014 , 83, 203-9	4
384	Endothelium-dependent vasoactivity of the human internal mammary artery. 2014 , 25, 266-74	7
383	Exploring the Use of the Suzuki Coupling Reaction in the Synthesis of 4?-Alkyl-2?-hydroxyacetophenones. 2014 , 25, 564-568	1
382	Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury. 2014 , 19, 83-96	62
381	Anti-inflammatory and anti-proliferative effects of CBS3830 in arterialized vein grafts in rats. 2014 , 36, 397-403	2
380	Asymmetric dimethylarginine and oxidative stress following coronary artery bypass grafting: associations with postoperative outcome. 2014 , 45, e136-41	12
379	Possible roles of 5-HT in vein graft failure due to intimal hyperplasia 5-HT, nitric oxide and vein graft. 2014 , 44, 213-8	1
378	Plateletcrit. A platelet marker associated with saphenous vein graft disease. 2014 , 39, 142-8	40
377	Macrophages control vascular stem/progenitor cell plasticity through tumor necrosis factor- α -mediated nuclear factor- κ B activation. 2014 , 34, 635-43	28
376	Role of Girdin in intimal hyperplasia in vein grafts and efficacy of atelocollagen-mediated application of small interfering RNA for vein graft failure. 2014 , 60, 479-489.e5	14
375	Management of antiplatelet therapy resistance in cardiac surgery. 2014 , 147, 855-62	9
374	Safety and effectiveness of drug-eluting versus bare-metal stents in saphenous vein bypass graft percutaneous coronary interventions: insights from the Veterans Affairs CART program. 2014 , 64, 1825-36	29
373	Preoperative neutrophil-lymphocyte ratio and saphenous vein graft patency after coronary artery bypass grafting. 2014 , 20, 819-24	24
372	Saphenous vein graft disease and neutrophil-to-lymphocyte ratio. 2014 , 20, 755-6	0
371	Enhanced accumulation of LDLs within the venous graft wall induced by elevated filtration rate may account for its accelerated atherogenesis. 2014 , 236, 198-206	8

370	Cross talk between vascular smooth muscle cells and monocytes through interleukin-1 β /interleukin-18 signaling promotes vein graft thickening. 2014 , 34, 2001-11	30
369	Smooth muscle cells from the anastomosed artery are the major precursors for neointima formation in both artery and vein grafts. 2014 , 109, 431	18
368	Coronary artery bypass graft: why is the saphenous vein prone to intimal hyperplasia?. 2014 , 92, 531-45	22
367	Cardiac markers following cardiac surgery and percutaneous coronary intervention. 2014 , 34, 99-111, vii	2
366	The impact of vessel clamps on endothelial integrity and function of saphenous vein grafts. 2014 , 28, 1113-22	2
365	Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery. 2014 , 97, 824-30	10
364	Type 2 diabetes impairs venous, but not arterial smooth muscle cell function: possible role of differential RhoA activity. 2014 , 15, 141-8	19
363	Outcomes of percutaneous coronary intervention of chronic total saphenous vein graft occlusions in the contemporary era. 2014 , 83, 1025-32	8
362	Biomechanical regulation of vascular smooth muscle cell functions: from in vitro to in vivo understanding. 2014 , 11, 20130852	110
361	Acute occlusion of the left internal mammary artery graft in the late postoperative period. 2014 , 10, 51-53	3
360	Protected coronary arteries: do open grafts pave the way to survival?. <i>JACC: Cardiovascular Imaging</i> , 2014 , 7, 590-2	8.4
359	Intervention for Failed Grafts. 2014 , 117-125	
358	Mediastinitis after coronary artery bypass grafting increases the incidence of left internal mammary artery obstruction. 2014 , 11, 594-600	6
357	Establishment of a rat autogenous arteriovenous fistula model following 5/6 nephrectomy. 2015 , 10, 219-224	2
356	Saphenous Vein Graft Disease Is Associated with a Low Serum Erythropoietin Level. 2015 , 24, 544-7	2
355	SAPHENOUS VEIN GRAFT PATENCY AFTER GEOMETRY REMODELING. 2015 , 15, 1540051	0
354	Arterial levels of oxygen stimulate intimal hyperplasia in human saphenous veins via a ROS-dependent mechanism. 2015 , 10, e0120301	6
353	In-stent neoatherosclerosis and distal embolization: lesion architecture, composition, and PCI compression. 2015 , 85, 573-4	

352	The 100 most cited publications in cardiac surgery: a bibliometric analysis. 2015 , 184, 91-9	33
351	Internal thoracic artery: anatomical and biological characteristics revisited. 2015 , 23, 88-99	21
350	Reversion-inducing-cysteine-rich protein with Kazal motif is involved in intimal hyperplasia in carotid arteries: a new insight in the prevention of restenosis after vascular angioplasty. 2015 , 29, 1293-9	1
349	MK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasia. 2015 , 7, 291ra95	35
348	Inhibitory effect of adenosine on intimal hyperplasia and proliferation of smooth muscle cells in a carotid arterial anastomosis animal model. 2015 , 23, 124-31	5
347	HEMODYNAMIC COMPARISON BETWEEN NORMAL GRAFT AND Y-TYPE GRAFT IN CORONARY ARTERY BYPASS GRAFTING: A NUMERICAL STUDY USING 0D/3D COUPLING METHOD. 2015 , 15, 1550053	5
346	Bilateral internal mammary artery grafting in obese: outcomes, concerns and controversies. 2015 , 16, 158-62	7
345	Soluble Jagged-1 inhibits restenosis of vein graft by attenuating Notch signaling. 2015 , 100, 9-16	9
344	Flow patterns in externally stented saphenous vein grafts and development of intimal hyperplasia. 2015 , 150, 871-8	44
343	Transient receptor potential channel M2 contributes to neointimal hyperplasia in vascular walls. 2015 , 1852, 1360-71	6
342	Angiographic and clinical results of everolimus-eluting stent utilization in saphenous vein graft lesions (ARES). 2015 , 184, 433-435	1
341	Numerical analysis of Venous External Scaffolding Technology for Saphenous Vein Grafts. 2015 , 48, 2090-5	8
340	Arterial blood pressure and vascular function in human saphenous vein. 2015 , 30, 233-8	3
339	A novel composite coronary bypass graft strategy using the saphenous vein bridge: could the venous valves induce worse patency results?. 2015 , 47, 940	1
338	Reply to Lobo Filho et al. 2015 , 47, 940-1	
337	Water-soluble jack-knife prawn extract inhibits 5-hydroxytryptamine-induced vasoconstriction and platelet aggregation in humans. 2015 , 6, 444-9	1
336	Bilateral internal mammary artery grafting: rationale and evidence. 2015 , 16, 133-9	26
335	The ADP antagonist MRS2179 regulates the phenotype of smooth muscle cells to limit intimal hyperplasia. 2015 , 29, 23-9	8

334	FSP-1 Impairs the Function of Endothelium Leading to Failure of Arteriovenous Grafts in Diabetic Mice. 2015 , 156, 2200-10	4
333	Clinical evaluation of the eSVS Mesh: First-in-Man trial outcomes. 2015 , 61, 178-83	12
332	A Randomized Trial of External Stenting for Saphenous Vein Grafts in Coronary Artery Bypass Grafting. 2015 , 99, 2039-45	63
331	Efforts to improve bypass graft patency have not been "in vein". 2015 , 150, 889-90	2
330	Bioprinting of Blood Vessels. 2015 , 337-350	4
329	Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial. 2015 , 13, 448-56	23
328	Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development: Implications for the Treatment of Vein Graft Failure. 2015 , 35, 2343-2353	38
327	Cells and stimuli in small-caliber blood vessel tissue engineering. 2015 , 10, 505-27	23
326	Efficient gene transfer and durable transgene expression in grafted rabbit veins. 2015 , 26, 47-58	6
325	Endothelial cells (ECs) for vascular tissue engineering: venous ECs are less thrombogenic than arterial ECs. 2015 , 9, 564-76	14
324	Sclerostin as a new key player in arteriovenous fistula calcification. 2015 , 40, 289-97	14
323	Relationship between neutrophil-to-lymphocyte ratio and saphenous vein graft disease in patients with coronary bypass. 2015 , 21, 25-9	18
322	A compact and automated ex vivo vessel culture system for the pulsatile pressure conditioning of human saphenous veins. 2016 , 10, E204-15	17
321	Drug-eluting stents appear superior to bare metal stents for vein-graft PCI in vessels up to a stent diameter of 4 mm. 2016 , 11, e17-e24	2
320	Neointima development in externally stented saphenous vein grafts. 2016 , 12, 334-339	3
319	Biomarkers in Coronary Artery Bypass Surgery: Ready for Prime Time and Outcome Prediction?. <i>Frontiers in Cardiovascular Medicine</i> , 2015 , 2, 39	5-4 13
318	The Case for Endothelial Preservation Pressure-Regulated Distension in the Preparation of Autologous Saphenous Vein Conduits in Cardiac and Peripheral Bypass Operations. 2016 , 3, 54	5
317	Molecular pathways activation in coronary artery bypass surgery: which role for pump avoidance?. 2016 , 17, 54-61	6

316	Molecular Signaling Pathways Behind the Biological Effects of Salvia Species Diterpenes in Neuropharmacology and Cardiology. 2016 , 30, 878-93	18
315	Strategies to Extend the Life of Saphenous Vein Grafts. 2016 , 581-593	
314	Deficiency of the TLR4 analogue RP105 aggravates vein graft disease by inducing a pro-inflammatory response. 2016 , 6, 24248	15
313	Vein graft disease in a knockout mouse model of hyperhomocysteinaemia. 2016 , 97, 447-456	1
312	Invasive Angiographic Assessment of Coronary Graft Patency. 2016 , 515-530	
311	Optical Coherence Tomography in Grafts. 2016 , 539-554	
310	Minor saphenous vein graft atherosclerosis only, whilst taking no medication, nearly a decade post coronary surgery. 2016 , 214, 338-9	
309	A case of dynamic segmental saphenous vein graft compression during diastole. 2016 , 58, e444-e447	
308	Vein graft failure: from pathophysiology to clinical outcomes. 2016 , 13, 451-70	155
307	Early CABG Failure. 2016 , 131-138	
306	Histological Analysis in Graft Disease. 2016 , 219-225	
305	Arterial Graft Failure. 2016 , 235-265	
304	Mechanisms of Venous Graft Failure. 2016 , 267-276	
303	Pathophysiology of Lesions in Coronary Bypass. 2016 , 291-308	
302	Imaging of Coronary Bypass Graft. 2016 , 477-482	
301	Lifelong Cyclic Mechanical Strain Promotes Large Elastic Artery Stiffening: Increased Pulse Pressure and Old Age-Related Organ Failure. 2016 , 32, 624-33	24
300	Postoperative Heparin-Mediated Extracorporeal Low-Density Lipoprotein Fibrinogen Precipitation Aphaeresis Prevents Early Graft Occlusion after Coronary Artery Bypass Grafting. 2016 , 2, e5-e9	1
299	Biomaterial-Based Approaches to Address Vein Graft and Hemodialysis Access Failures. 2016 , 37, 1860-1880	8

298	Advanced glycation end products impair the functions of saphenous vein but not thoracic artery smooth muscle cells through RAGE/MAPK signalling pathway in diabetes. 2016 , 20, 1945-55	8
297	Total arterial revascularization: A superior method of cardiac revascularization. 2016 , 57, 152-156	5
296	Aspirin dosage for the prevention of graft occlusion in people undergoing coronary surgery. 2016 ,	
295	Vein graft thrombi, a niche for smooth muscle cell colonization - a hypothesis to explain the asymmetry of intimal hyperplasia. 2016 , 14, 1095-104	12
294	Intraoperative Vein Graft Preservation: What Is the Solution?. 2016 , 102, 1736-1746	15
293	Patient-Specific Simulations Reveal Significant Differences in Mechanical Stimuli in Venous and Arterial Coronary Grafts. 2016 , 9, 279-90	25
292	Influence of stent implantation on erythrocyte aggregation in human native coronary arteries and saphenous vein grafts. 2016 , 23, 637-645	4
291	OCT imaging of aorto-coronary vein graft pathology modified by external stenting: 1-year post-surgery. 2016 , 17, 1290-1295	21
290	Cardiac findings on non-gated chest computed tomography: A clinical and pictorial review. 2016 , 85, 435-51	11
289	Coronary bypass graft perforation during percutaneous intervention. 2016 , 17, 48-53	8
288	MicroRNA-221 sponge therapy attenuates neointimal hyperplasia and improves blood flows in vein grafts. 2016 , 208, 79-86	24
287	Mouse Models of Vascular Diseases. 2016 ,	2
286	Soluble N-cadherin: A novel inhibitor of VSMC proliferation and intimal thickening. 2016 , 78, 53-62	6
285	Fabrication of keratin/fibroin membranes by electrospinning for vascular tissue engineering. 2016 , 4, 237-244	28
284	Hemodynamics of the string phenomenon in the internal thoracic artery grafted to the left anterior descending artery with moderate stenosis. 2016 , 49, 983-991	26
283	Association Between Platelet to Lymphocyte Ratio and Saphenous Vein Graft Disease. 2016 , 67, 133-8	23
282	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial. 2017 , 6, 164-172	7
281	Relationship between Serum Albumin Level and Monocyte-to-High-Density Lipoprotein Cholesterol Ratio with Saphenous Vein Graft Disease in Coronary Bypass. 2017 , 65, 315-321	17

280	Local application of paeonol prevents early restenosis: a study with a rabbit vein graft model. 2017 , 212, 278-287	10
279	Distal Anastomosis Support for Coronary Artery Bypass Grafting: A New Surgical Technique and Current Outcomes. 2017 , 26, 1224-1230	2
278	Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights. 2017 , 69, 119-127	33
277	Recombinant soluble apyrase APT102 inhibits thrombosis and intimal hyperplasia in vein grafts without adversely affecting hemostasis or re-endothelialization. 2017 , 15, 814-825	5
276	Stable CAD and Approach to Chronic Chest Pain. 2017 , 65-91	
275	Once versus twice daily aspirin after coronary bypass surgery: a randomized trial. 2017 , 15, 889-896	11
274	Mouse models of atherosclerosis: a historical perspective and recent advances. 2017 , 16, 12	88
273	The development and mechanical characterisation of a novel reinforced venous conduit that mimics the mechanical properties of an arterial wall. 2017 , 71, 23-31	5
272	Aspirin Use Prior to Coronary Artery Bypass Grafting Surgery: a Systematic Review. 2017 , 19, 18	4
271	Bolus injections of novel thrombogenic site-targeted fusion proteins comprising annexin-V and Kunitz protease inhibitors attenuate intimal hyperplasia after balloon angioplasty. 2017 , 240, 339-346	3
270	High expression of ubiquitin-specific peptidase 39 is associated with the development of vascular remodeling. 2017 , 15, 2567-2573	2
269	Percutaneous intervention versus coronary artery bypass graft surgery in left main coronary artery stenosis: a systematic review and meta-analysis. 2017 , 15, 84	13
268	Intensive versus moderate atorvastatin therapy and one-year graft patency after CABG: Rationale and design of the ACTIVE (Aggressive Cholesterol Therapy to Inhibit Vein Graft Events) randomized controlled trial (NCT01528709). 2017 , 59, 98-104	8
267	Gradual loading ameliorates maladaptation in computational simulations of vein graft growth and remodelling. 2017 , 14,	24
266	Unimolecular Micelle-Based Hybrid System for Perivascular Drug Delivery Produces Long-Term Efficacy for Neointima Attenuation in Rats. 2017 , 18, 2205-2213	20
265	Graft Occlusion and Graft Size Changes in Complex Internal Carotid Artery Aneurysm Treated by Extracranial to Intracranial Bypass Using High-Flow Grafts with Therapeutic Internal Carotid Artery Occlusion. 2017 , 81, 672-679	15
264	A prospective study of external stenting of saphenous vein grafts to the right coronary artery: the VEST II study. 2017 , 51, 952-958	23
263	Characteristics and outcomes of patients undergoing percutaneous coronary intervention within 1 year of coronary artery bypass graft surgery. 2017 , 90, 186-193	2

262	The relationship between lymphocyte-to-monocyte ratio and saphenous vein graft patency in patients with coronary artery bypass graft. 2017 , 11, 867-876	11
261	Mechanisms, Consequences, and Prevention of Coronary Graft Failure. <i>Circulation</i> , 2017 , 136, 1749-1764	16.7 113
260	Tumor necrosis factor alpha-stimulated gene-6 (TSG-6) inhibits the inflammatory response by inhibiting the activation of P38 and JNK signaling pathway and decreases the restenosis of vein grafts in rats. 2017 , 32, 1536-1545	4
259	Activation and inflammation of the venous endothelium in vein graft disease. 2017 , 265, 266-274	31
258	Protein kinase CK2 inhibition suppresses neointima formation via a proline-rich homeodomain-dependent mechanism. 2017 , 99, 34-44	4
257	Intimal hyperplasia induced by vascular intervention causes lipoprotein retention and accelerated atherosclerosis. 2017 , 5, e13334	20
256	Attenuation of Maladaptive Responses in Aortic Adventitial Fibroblasts through Stimuli-Triggered siRNA Release from Lipid-Polymer Nanocomplexes. 2017 , 1, 1700099	4
255	A computational fluid-structure interaction analysis of coronary Y-grafts. 2017 , 47, 117-127	15
254	Linking Gene Dynamics to Intimal Hyperplasia: A Predictive Model of Vein Graft Adaptation. 2017 , 108, 1842-1851	2
253	Ultrastructural and histomorphologic properties of the internal thoracic artery: implications for coronary revascularization. 2017 , 28, 518-527	5
252	Management and Prevention of Saphenous Vein Graft Failure: A Review. 2017 , 6, 203-223	51
251	Stent collapse caused by balloon occlusion and aspiration system in saphenous vein graft intervention. 2017 , 16, 119-122	
250	The use of preoperative aspirin in cardiac surgery: A systematic review and meta-analysis. <i>Journal of Cardiac Surgery</i> , 2017 , 32, 758-774	1,3 21
249	A comparison of postoperative morphometric and hemodynamic changes between saphenous vein and left internal mammary artery grafts. 2017 , 5, e13487	8
248	Differential Impact of Serial Measurement of Nonplatelet Thromboxane Generation on Long-Term Outcome After Cardiac Surgery. 2017 , 6,	1
247	A Rabbit Model for Testing Helper-Dependent Adenovirus-Mediated Gene Therapy for Vein Graft Atherosclerosis. 2017 , 7, 96-111	2
246	Pedicle Vein Grafts in Coronary Surgery: Perioperative Data From a Randomized Trial. 2017 , 104, 1313-1317	10
245	Vascular Adaptation: Pattern Formation and Cross Validation between an Agent Based Model and a Dynamical System. 2017 , 429, 149-163	12

244	Superior long term outcome associated with native vessel versus graft vessel PCI following secondary PCI in patients with prior CABG. 2017 , 228, 563-569		9
243	Contemporary use of arterial and venous conduits in coronary artery bypass grafting: anatomical, functional and clinical aspects. <i>Netherlands Heart Journal</i> , 2017 , 25, 4-13	2.2	15
242	5.4 Biomaterials and the Microvasculature. 2017 , 67-87		
241	Promoting Vasa Vasorum Neovascularization of Vein Grafts Extenuates Hypoxia of the Wall and Its Subsequent Influence on Intimal Hyperplasia. 2017 , 130, 1327-1332		
240	Enhancement of Nitric Oxide Production Is Responsible for Minimal Intimal Hyperplasia of Autogenous Rabbit Arterial Grafts. 2017 , 81, 1222-1230		3
239	Calcification of Human Saphenous Vein Associated with Endothelial Dysfunction: A Pilot Histopathophysiological and Demographical Study. 2017 , 4, 6		5
238	Linking gene dynamics to vascular hyperplasia - Toward a predictive model of vein graft adaptation. 2017 , 12, e0187606		7
237	Histomorphometric and Immunohistochemical Study of Early Adaptative Response of the Vascular Wall in a Termino-Terminal Microsurgical Model of Femoral Vessels in Wistar Rat. 2017 , 35, 479-487		
236	The Choice of Graft Conduits in Coronary Artery Bypass Grafting. 2017 ,		2
235	Cyclic stretch-induced Crp3 sensitizes vascular smooth muscle cells to apoptosis during vein arterialization remodeling. 2018 ,		5
234	Graft failure and recurrence of symptoms after coronary artery bypass grafting. 2018 , 52, 113-119		14
233	Implications of coronary artery bypass grafting and percutaneous coronary intervention on disease progression and the resulting changes to the physiology and pathology of the native coronary arteries. 2018 , 54, 809-816		6
232	Role of smooth muscle cells in coronary artery bypass grafting failure. 2018 , 114, 601-610		44
231	Early animal model evaluation of an implantable contrast agent to enhance magnetic resonance imaging of arterial bypass vein grafts. 2018 , 59, 1074-1081		
230	Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database. 2018 , 92, 659-665		2
229	Pulmonary Venous Remodeling in Pulmonary Hypertension: The Veins Take Center Stage. <i>Circulation</i> , 2018 , 137, 1811-1813	16.7	5
228	Procedural Results and Immediate Outcomes following De Novo Saphenous Venous Graft Interventions. 2018 , 27, 144-150		
227	Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909). 2018 , 68, 45-51		6

226	Eight-year follow-up of the Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) trial. 2018 , 155, 212-222.e2	15
225	No improvements in long-term outcome after coronary artery bypass grafting with arterial grafts as a second conduit: a Swedish nationwide registry study. 2018 , 53, 448-454	16
224	High-Risk Patients and Interventions. 2018 , 237-260	
223	Biomechanics and Mechanobiology of Saphenous Vein Grafts. 2018 , 140,	12
222	Myocardial revascularization: the evolution of the STS database and quality measurement for improvement. 2018 , 34, 222-229	0
221	Drug-Eluting Stents Versus Bare-Metal Stents in Saphenous Vein Graft Intervention. 2018 , 11, e007045	9
220	Antegrade cardioplegia as a possible cause of acute saphenous vein endothelial damage in patients undergoing on pump coronary artery bypass surgery. 2018 , 10, 4302-4310	1
219	Long-term performance of an external stent for saphenous vein grafts: the VEST IV trial. 2018 , 13, 117	31
218	Current role of saphenous vein graft in coronary artery bypass grafting. 2018 , 34, 245-250	3
217	Long-term clinical outcomes after coronary artery bypass grafting with pedicled saphenous vein grafts. 2018 , 13, 122	7
216	Bilateral internal thoracic artery grafting: or composite?. 2018 , 7, 673-680	5
215	Vasa vasorum of the failed aorto-coronary venous grafts. 2018 , 40, 769-778	7
214	Graft patency in diabetic patients and the discomfort of thought. 2018 , 155, 2316-2321	2
213	Rationale for administering beta-blocker therapy to patients undergoing coronary artery bypass surgery: a systematic review. 2018 , 17, 805-813	6
212	Inflammation in Vein Graft Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2018 , 5, 3	5-4 53
211	Mechanotransduction in Coronary Vein Graft Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2018 , 5, 20	5-4 11
210	Local Adipose-Associated Mediators and Adaptations Following Arteriovenous Fistula Creation. 2018 , 3, 970-978	2
209	Outcomes of Fractional Flow Reserve-Based Deferral in Saphenous Vein Graft Narrowing. 2018 , 122, 723-728	4

208	Re-exploration for bleeding associated with increased incidence of the need for reintervention after coronary artery bypass graft surgery. 2019 , 28, 214-221		4
207	Peripheral Blood Stem Cells. 2019 , 307-333		
206	Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial. 2019 , 157, 151-161.e1		10
205	A mathematical model to evaluate hemodynamic effects of the graft anastomosis in coronary surgery. 2019 , 16, 106-108		1
204	Inhibition of the Akt1-mTORC1 Axis Alters Venous Remodeling to Improve Arteriovenous Fistula Patency. 2019 , 9, 11046		12
203	Second-generation drug-eluting stents versus bare-metal stents in saphenous vein grafts: is the choice more complicated than before?. 2019 , 11, S385-S389		0
202	Arterial Grafts for Coronary Bypass: A Critical Review After the Publication of ART and RADIAL. <i>Circulation</i> , 2019 , 140, 1273-1284	16.7	28
201	Dimethylarginine Dimethylaminohydrolase 1 Polymorphisms and Venous Intimal Hyperplasia in Hemodialysis Patients. 2019 , 50, 454-464		1
200	Does Early Graft Patency Benefit from Perioperative Statin Therapy? A Propensity Score-Matched Study of Patients Undergoing Off-Pump Coronary Artery Bypass Surgery. 2019 , 2019, 1582183		0
199	Differences in Expression of Genes Involved in Bone Development and Morphogenesis in the Walls of Internal Thoracic Artery and Saphenous Vein Conduits May Provide Markers Useful for Evaluation Graft Patency. 2019 , 20,		5
198	State-of-the-Art Coronary Artery Bypass Grafting: Patient Selection, Graft Selection, and Optimizing Outcomes. 2019 , 8, 173-198		8
197	Platelet to Lymphocyte Ratio in Cardiovascular Diseases: A Systematic Review. 2019 , 70, 802-818		49
196	Dual platelet antiaggregation therapy after myocardial revascularization surgery. 2019 , 65, 316-318		
195	New-generation drug eluting stent vs. bare metal stent in saphenous vein graft - 1 year outcomes by a propensity score ascertainment (SVG Baltic Registry). 2019 , 292, 56-61		1
194	Comparison of venous repair results using either arterial or vein grafts in a crush-avulsion injury model. 2019 , 49, 435-441		1
193	Long-term follow-up of covered stent implantation for various coronary artery diseases. 2019 , 94, 571-577		8
192	Shedding Light Into Late Saphenous Vein Graft Failure. 2019 , 20, 6-8		
191	Intraoperative storage of saphenous vein grafts in coronary artery bypass grafting. 2019 , 16, 989-997		5

190	Drug-Eluting Versus Bare Metal Stents in Saphenous Vein Graft Intervention: An Updated Comprehensive Meta-Analysis of Randomized Trials. 2019 , 20, 758-767	3
189	Uncertainty quantification of simulated biomechanical stimuli in coronary artery bypass grafts. 2019 , 345, 402-428	19
188	MicroRNA-145-loaded poly(lactic-co-glycolic acid) nanoparticles attenuate venous intimal hyperplasia in a rabbit model. 2019 , 157, 2242-2251	11
187	Pathology of valved venous homografts used as right ventricle-to-pulmonary artery conduits in congenital heart disease surgery. 2019 , 157, 342-350.e3	4
186	Antiplatelet effects of ticagrelor versus clopidogrel after coronary artery bypass graft surgery: A single-center randomized controlled trial. 2019 , 158, 430-437.e4	9
185	An appropriately sized soft polyester external stent prevents enlargement and neointimal hyperplasia of a saphenous vein graft in a canine model. 2019 , 43, 577-583	4
184	MicroRNA-146a sponge therapy suppresses neointimal formation in rat vein grafts. 2019 , 71, 125-133	2
183	Endothelial repair is dependent on CD11c leukocytes to establish regrowing endothelial sheets with high cellular density. 2019 , 105, 195-202	1
182	Is 300 Seconds ACT Safe and Efficient during MiECC Procedures?. 2019 , 67, 191-202	8
181	Angiographic appearance of patent saphenous vein grafts more than 25 years after coronary artery bypass grafting. 2020 , 68, 177-180	1
180	Development of a risk score for early saphenous vein graft failure: An individual patient data meta-analysis. 2020 , 160, 116-127.e4	15
179	Preventing treatment failures in coronary artery disease: what can we learn from the biology of in-stent restenosis, vein graft failure, and internal thoracic arteries?. 2020 , 116, 505-519	30
178	Saphenous vein grafts in contemporary coronary artery bypass graft surgery. 2020 , 17, 155-169	58
177	Decreased Jagged1 expression in vascular smooth muscle cells delays endothelial regeneration in arteriovenous graft. 2020 , 116, 2142-2155	4
176	The placental growth factor attenuates intimal hyperplasia in vein grafts by improving endothelial dysfunction. 2020 , 868, 172856	1
175	CHA2DS2-Vasc score and saphenous vein graft disease in patients with coronary artery bypass graft surgery. 2020 , 31, 243-247	3
174	A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery-Rationale and design of the POPular CABG trial. <i>American Heart Journal</i> , 2020 , 220, 237-245	4.9 2
173	Towards a Saphenous Vein Graft Moratorium. 2020 , 28, 236-239	

172	Impact of lipid levels and high-intensity statins on vein graft patency after CABG: Midterm results of the ACTIVE trial. <i>Journal of Cardiac Surgery</i> , 2020 , 35, 3286-3293	1.3	4
171	The Effect of an Atherogenic Diet and Acute Hyperglycaemia on Endothelial Function in Rabbits Is Artery Specific. 2020 , 12,		3
170	Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Circulation</i> , 2020 , 142, 1799-1807	16.7	13
169	Antiplatelet Therapy after Coronary Artery Bypass Graft Surgery, Inconsistency of Clinical Practice and Clinical Significance of Proven Resistance to Antiplatelet Agents. 2020 ,		
168	Molecular differences between arterial and venous grafts in the first year after coronary artery bypass grafting. 2020 , 154, 405-419		0
167	NF- κ B inhibition prevents acute shear stress-induced inflammation in the saphenous vein graft endothelium. 2020 , 10, 15133		9
166	Influence of lipoproteins and antiplatelet agents on vein graft patency 1 year after coronary artery bypass grafting. 2020 ,		3
165	Commentary: Yin and Yang: Antiplatelet and lipid-lowering therapies to prevent vein graft thrombosis and atherosclerosis after coronary artery bypass graft surgery. 2020 ,		1
164	Bioinspired Vascular Grafts. 2020 , 1-20		
163	[Thirty-five-year angiographic follow-up of the first coronary bypass surgery by internal mammary artery in Hungary]. 2020 , 161, 354-358		
162	Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study. 2020 , 15, 155		1
161	Vein Source Influences Neointimal Response in Rat Vein-to-Artery Grafts. 2020 , 254, 165-169		
160	Saphenous vein graft disease, pathophysiology, prevention, and treatment. A review of the literature. <i>Journal of Cardiac Surgery</i> , 2020 , 35, 1314-1321	1.3	11
159	Low Wall Shear Stress Is Associated with Saphenous Vein Graft Stenosis in Patients with Coronary Artery Bypass Grafting. 2021 , 14, 770-781		6
158	No-touch saphenous vein grafts in coronary artery surgery (SWEDEGRAFT): Rationale and design of a multicenter, prospective, registry-based randomized clinical trial. <i>American Heart Journal</i> , 2020 , 224, 17-24	4.9	4
157	Safety and Efficacy of Embolic Protection Devices in Saphenous Vein Graft Interventions: A Propensity Score Analysis-Multicenter SVG PCI PROTECTA Study. 2020 , 9,		1
156	Atorvastatin Reduces Fibrin Deposition and Macrophage Accumulation, and Improves Primary Patency Duration and Maturation of Murine Arteriovenous Fistula. 2020 , 31, 931-945		5
155	Association of hypoxia and mitochondrial damage associated molecular patterns in the pathogenesis of vein graft failure: a pilot study. 2021 , 229, 38-52		8

- 154 Modulating the Bioactivity of Nitric Oxide as a Therapeutic Strategy in Cardiac Surgery. **2021**, 257, 178-188 2
- 153 Coronary Artery Bypass: Review of Surgical Techniques and Impact on Long-Term Revascularization Outcomes. **2021**, 10, 89-109 4
- 152 Commentary: Why not MAG-nify the benefit in patients with diabetes?. **2021**,
- 151 Percutaneous coronary intervention in saphenous vein grafts after coronary artery bypass grafting: a systematic review and meta-analysis. **2021**, 55, 245-253 1
- 150 C-Reactive Protein to Albumin Ratio in Patients With Saphenous Vein Graft Disease. **2021**, 72, 770-775 7
- 149 Emerging roles of protein O-GlcNAcylation in cardiovascular diseases: Insights and novel therapeutic targets. **2021**, 165, 105467 6
- 148 External stenting of vein grafts in coronary artery bypass grafting: interim results from a two centers prospective study. **2021**, 16, 74 1
- 147 External stenting and disease progression in saphenous vein grafts two years after coronary artery bypass grafting: A multicenter randomized trial. **2021**, 5 5
- 146 The Use of Radial Artery for CABG: An Update. **2021**, 2021, 5528006 2
- 145 Glabridin Relaxes Vascular Smooth Muscles by Activating BK Channels and Inhibiting Phosphodiesterase in Human Saphenous Vein. **2021**, 41, 381-389 0
- 144 Revascularisation of type 2 diabetics with coronary artery disease: Insights and therapeutic targeting of O-GlcNAcylation. **2021**, 31, 1349-1356 4
- 143 Histopathologic evaluation of saphenous vein grafts in patients with type II diabetes mellitus undergoing coronary artery bypass grafting. **2021**, 52, 107328 1
- 142 Efficacy evaluation of anforming tissue adhesive hydrogel as sealant for lung and vascular injury. **2021**, 16, 2
- 141 Saphenous vein harvesting techniques for coronary artery bypass grafting: a systematic review and meta-analysis. **2021**, 1 1
- 140 Saphenous vein valve assessment utilizing upright CT to potentially improve graft assessment for bypass surgery. **2021**, 11, 11602 0
- 139 A Novel Risk Scoring Tool to Predict Saphenous Vein Graft Occlusion After Cardiac Artery Bypass Graft Surgery. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 670045 5-4 1
- 138 Reopening of the occluded saphenous vein composite grafts after coronary artery bypass grafting. *Journal of Cardiac Surgery*, **2021**, 36, 4061-4067 1-3 0
- 137 Learning process and results in endoscopic saphenous vein harvesting technique. **2021**, 5, 807-812

136	Vascular Smooth Muscle Cell Subpopulations and Neointimal Formation in Mouse Models of Elastin Insufficiency. 2021 , 41, 2890-2905	4
135	Increased patency with comparable mortality and revascularization risk: Is the case for no-touch vein harvesting open and shut?. <i>Journal of Cardiac Surgery</i> , 2021 , 36, 4376-4377	13
134	Role of PDE10A in vascular smooth muscle cell hyperplasia and pathological vascular remodeling. 2021 ,	0
133	Bioinspired Vascular Grafts. 2021 , 3-22	
132	Metalloproteinases in Acute Venous Occlusion. 2013 , 141-151	1
131	Vascular Aging. 2005 , 517-547	1
130	Native Coronary Artery and Bypass Graft Atherosclerosis. 2015 , 273-301	2
129	Autogenous Vein Grafts. 2010 , 1316-1334	2
128	Interaction between the apelinergic system and ACE2 in the cardiovascular system: therapeutic implications. 2020 , 134, 2319-2336	10
127	Exacerbated vein graft arteriosclerosis in protein kinase Cdelta-null mice. 2001 , 108, 1505-12	107
126	Exacerbated vein graft arteriosclerosis in protein kinase C β mice. 2001 , 108, 1505-1512	199
125	Arterial reconstruction using the donor iliofemoral vein in living renal transplantation with multiple renal arteries: a case report and a literature review. 2020 , 21, 190	4
124	Distal Protection Devices. 2008 , 870-879	1
123	Total Arterial Revascularization: Bypassing Antiquated Notions to Better Alternatives for Coronary Artery Disease. 2016 , 22, 107-114	11
122	Release of Intracoronary Microparticles during Stent Implantation into Stable Atherosclerotic Lesions under Protection with an Aspiration Device. 2015 , 10, e0124904	13
121	Papaverine Prevents Vasospasm by Regulation of Myosin Light Chain Phosphorylation and Actin Polymerization in Human Saphenous Vein. 2016 , 11, e0154460	7
120	Minimally invasive saphenous vein harvesting using a laryngoscope: procedural, functional, and morphologic evaluation. 2005 , 8, E425-30	4
119	Influence of angiotensin converting enzyme insertion/deletion polymorphism on long-term total graft occlusion after coronary artery bypass surgery. 2005 , 8, E373-7	9

118	An Alternative Strategy for Reducing Tissue Immunogenicity Using Ice-Free Cryopreservation. 2016 , 3,	2
117	Current State of the Art in Approaches to Saphenous Vein Graft Interventions. 2017 , 12, 85-91	11
116	Predictive Value of Mean Platelet Volume in Saphenous Vein Graft Disease. 2018 , 33, 317-322	9
115	On-Pump Coronary Artery Bypass Graft: The State of the Art. 2019 , 14, 106-115	2
114	Advances in vein graft intervention. 2010 , 2, 735-754	2
113	Advancing tissue-engineered vascular grafts via their endothelialization and mechanical conditioning. <i>Journal of Cardiovascular Surgery</i> , 2020 , 61, 555-576	0.7 6
112	Russian clinical guidelines Coronary artery bypass grafting in patients with ischemic heart disease: rehabilitation and secondary prevention. 2016 , 7, 5-71	35
111	VENOUS CONDUITS IN CORONARY SURGERY: OLD PROBLEMS IN NEW SOLUTIONS. 2019 , 34, 24-32	1
110	A periadventitial sirolimus-releasing mesh decreased intimal hyperplasia in a rabbit model. 2011 , 60, 585-8	6
109	A meta-analysis of randomized controlled trials on mid-term angiographic outcomes for radial artery versus saphenous vein in coronary artery bypass graft surgery. 2013 , 2, 401-7	28
108	Why is the mammary artery so special and what protects it from atherosclerosis?. 2013 , 2, 519-26	125
107	How I choose conduits and configure grafts for my patients-rationales and practices. 2013 , 2, 527-32	9
106	Novel no touch technique of saphenous vein harvesting: Is great graft patency rate provided?. 2016 , 19, 481-8	11
105	Drug-eluting stents versus bare metal stents for saphenous vein graft revascularisation: a meta-analysis of randomised trials. 2018 , 14, 215-223	9
104	Percutaneous coronary interventions in saphenous vein grafts: the more things change, the more they stay the same. 2011 , 7, 893-5	1
103	Influences of Geometric Configurations of Bypass Grafts on Hemodynamics in End-to-Side Anastomosis. 2011 , 44, 89-98	1
102	Administration of perivascular cyanoacrylate for the prevention of cellular damage in saphenous vein grafts: an experimental model. 2016 , 27, 159-163	3
101	Bilateral Internal Thoracic Artery Graft in Coronary Artery Bypass Grafting. 2019 , 25, 21-26	0

- 100 Graft flow assessment and early coronary artery bypass graft failure: a computed tomography analysis. **2021**,
- 99 Association between SYNTAX II Score and late saphenous vein graft failure in patients undergoing isolated coronary artery bypass graft surgery. **2021**, 67, 1093-1101 1
- 98 Association of CHADS-VASc score with thrombus burden in patients with acute myocardial infarction undergoing SVG-PCI. **2021**, 1 1
- 97 Late Outcomes of In Situ Versus Composite Bilateral Internal Thoracic Artery Revascularization. **2021**, 112, 1441-1446 1
- 96 Clinical Properties and Healing Characteristics of e-PTFE Vascular Grafts and Their Effects on Long-Term Patency. **2003**,
- 95 Translating Nanotechnology to Vascular Disease. **2004**,
- 94 The Use of Proteomics to Map Phenotypic Heterogeneity of the Endothelium. **2005**, 132-146
- 93 Extracellular Superoxide Dismutase with Vaccinia Virus Anti-inflammatory Protein 35K or Tissue Inhibitor of Metalloproteinase-1: Combination Gene Therapy in the Treatment of Vein Graft Stenosis in Rabbits. **2006**, 060317071703001
- 92 Engineering of Blood Vessels from Acellular Collagen Matrices Coated with Human Endothelial Cells. **2006**, 060913044658035
- 91 Inhibition of adhesion molecule expression on human venous endothelial cells by non-viral siRNA transfection. **2006**, 10, 1-9
- 90 Recent Strategies to Improve Graft Performance in Patients Undergoing Coronary Artery Bypass Surgery. Are Best Results Achieved by Improved Surgical Techniques of Graft Preparation?. **2009**, 371-397
- 89 Coronary Artery Bypass Surgery: Science and Practice. **2009**, 471-485
- 88 Antiplatelet therapy in coronary artery disease after surgical revascularization. **2009**, 15, 256-261
- 87 ISCHEMIC HEART DISEASE: BYPASS GRAFT ANGIOGRAPHY. **2010**, 123-132
- 86 Percutaneous Coronary Intervention for the Treatment of Saphenous Vein Grafts. 416-427
- 85 Arterial Revascularization of Coronary Artery Disease. 457-472
- 84 Aspirin resistance after coronary artery bypass grafting. **2010**, 52, 52-58
- 83 Pathophysiology of atherosclerosis. **2011**, 54-62

- 82 Saphenous Vein Graft Disease. **2011**, 36-41
- 81 Radial Artery Harvest for Cerebral Revascularization. **2011**, 119-124
- 80 Predoperatsionnaya terapiya statinamiu patsientov s ishemicheskoy boleznMyu serdtsa. **2011**, 2, 51-54 1
- 79 Coronary Artery Disease: Development and Progression. **2012**, 21-28 0
- 78 Paclitaxel-eluting stents reduce neointimal hyperplasia compared to bare metal stents in saphenous vein grafts: intravascular ultrasonography analysis of the SOS (Stenting of Saphenous Vein Grafts) trial. **2011**, 7, 948-54 3
- 77 Intraoperative Transit-Time Flow Measurement is Not Altered in Venous Bypass Grafts Covered by the eSVS Mesh. **2013**, 8, 37-41 1
- 76 PERIPROCEDURAL MYOCARDIAL DAMAGE. **2013**, 12, 95-101
- 75 Native Coronary Artery and Bypass Graft Atherosclerosis. **2014**, 1-31
- 74 Laser Revascularisation in Saphenous Vein Grafts. **2015**, 69-82
- 73 Association between platelet to lymphocyte ratio and saphenous vein graft disease in patients with stable angina pectoris. **2016**, 16, 349-53 7
- 72 Single Photon Emission Computed Tomography Before and After CABG. **2016**, 505-513
- 71 The Use of Protection Devices in Vein Graft Intervention. **2016**, 665-674
- 70 Percutaneous Coronary Intervention of Saphenous Vein Graft Failure. **2016**, 595-602
- 69 Innate Immunity and Vein Graft Disease. **2016**, 309-316
- 68 Conventional Coronary Artery Bypass Graft Surgery. **2016**, 06, 55-60
- 67 Murine Models of Vein Grafting. **2016**, 143-155
- 66 Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. **2016**, 31, 106-14 3
- 65 Blood Tests to Determine the Risk for Graft Failure. **2016**, 473-475

- 64 Lipid Management and Graft Failure. **2016**, 341-349
- 63 Effectiveness and safety of preoperative aspirin therapy in patients undergoing elective coronary artery bypass grafting. **2017**, 10, 9
- 62 Fabrication and Characterization of Elastin-Crosslinked Silk Fibroin Material for Tissue Engineering. **2018**, 75, 80-83
- 61 Why Use the Radial Artery? The Saphenous Vein is the Second Graft of Choice for CABG in Brazil. **2019**, 34, 480-483 1
- 60 Early Stage of Atherosclerosis in Aortocoronary Saphenous Vein Grafts: Intravascular Ultrasound Study. **2019**, 34, 560-564
- 59 VENOUS CONDUITS IN CORONARY SURGERY: OLD PROBLEMS IN NEW SOLUTIONS. **2019**, 34, 24-32
- 58 Conduits for Coronary Artery Bypass Surgery. **2020**, 131-137
- 57 Reduced Function of Endothelial Nitric Oxide and Hyperpolarization in Artery Grafts with Poor Runoff. **2021**, 270, 2-11
- 56 Saphenous Vein Graft Disease Interventions. **2021**, 06, 199-208 1
- 55 Novel Strategies for the Prevention of Vein Graft Failure. **2006**, 303-310
- 54 Gene Therapy for Vein Graft Disease. **2006**, 311-320
- 53 Zelluläre und molekulare Mechanismen des Alterungsprozesses an Herz und Gefäßen. **2005**, 16-19
- 52 Il bypass. **2006**, 77-91
- 51 Toward the Prevention of Vein Graft Failure. **2008**, 158-176
- 50 Pathology of Coronary Artery Disease and Ischemic Heart Disease. **2009**, 31-43
- 49 Impact of Atherogenic Indexes in Saphenous Vein Graft Stenosis. *Arquivos Brasileiros De Cardiologia*, **2020**, 115, 538-544 1.2 1
- 48 Long-Term Clinical Outcomes of Percutaneous Coronary Intervention in Saphenous Vein Grafts in a Low to Middle-Income Country. **2020**, 12, e11496
- 47 Flow analysis of left internal thoracic artery in myocardial revascularization surgery using y graft. *Texas Heart Institute Journal*, **2006**, 33, 430-6 0.8 4

46	Acute anterior myocardial infarction due to aortosaphenous vein graft occlusion with very large thrombus burden. 2007 , 12, 203-5		3
45	MRI in the detection of stenosis in coronary artery bypass grafts: are invasive techniques still needed?. <i>Netherlands Heart Journal</i> , 2003 , 11, 1-4	2.2	1
44	Extensive deendothelialization and thrombogenicity in routinely prepared vein grafts for coronary bypass operations: facts and remedy. <i>International Journal of Clinical and Experimental Medicine</i> , 2009 , 2, 95-113		21
43	Scoring system for predicting saphenous vein graft patency in coronary artery bypass grafting. <i>Texas Heart Institute Journal</i> , 2010 , 37, 525-30	0.8	12
42	Long term outcomes of saphenous vein graft intervention in elderly patients with prior coronary artery bypass graft. <i>Journal of Geriatric Cardiology</i> , 2014 , 11, 26-31	1.7	3
41	Relative importance of patient, procedural and anatomic risk factors for early vein graft thrombosis after coronary artery bypass graft surgery. <i>Journal of Cardiovascular Surgery</i> , 2011 , 52, 877-85	0.7	12
40	Association between Plasma Fibrinogen Level and Saphenous Vein Graft Patency. <i>Acta Cardiologica Sinica</i> , 2014 , 30, 223-8	1.1	2
39	[Not Available]. <i>Acta Cardiologica Sinica</i> , 2014 , 30, 485-9	1.1	
38	Long-Term Outcomes in Coronary Artery Bypass Graft Patients Using Internal Thoracic Artery with Ipsilateral Arteriovenous Shunt for Hemodialysis. <i>Acta Cardiologica Sinica</i> , 2019 , 35, 387-393	1.1	
37	A Adiponectina Previne a Reestenose pela Inibiçã da Proliferaçã Celular em um Modelo de Enxerto Venoso em Ratos. <i>Arquivos Brasileiros De Cardiologia</i> , 2021 , 117, 1179-1188	1.2	2
36	Therapeutic-Dose Warfarin (International Normalized Ratio >1.6) Plus Aspirin Improved Long-Term Patency of Saphenous Vein Graft without Bleeding Complication.. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2022 , 28,	1.8	
35	Newly Developed Graft Failure Detected Using Computed Tomography Within 1 Year After Coronary Artery Bypass Grafting Surgery: One Single-Center Experience.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 779015	5.4	0
34	Stable Ischemic Heart Disease and Approach to Chronic Chest Pain. 2022 , 74-101		
33	Rationale and Design of a Randomized Trial Evaluating an External Support Device for Saphenous Vein Coronary Grafts.. <i>American Heart Journal</i> , 2021 , 246, 12-12	4.9	0
32	Acute shear stress and vein graft disease.. <i>International Journal of Biochemistry and Cell Biology</i> , 2022 , 144, 106173	5.6	0
31	Monitoring Cellular Proliferation, Migration, and Apoptosis Associated with Atherosclerosis Plaques In Vitro.. <i>Methods in Molecular Biology</i> , 2022 , 2419, 133-167	1.4	1
30	Influence of cholesterol level on long-term survival and cardiac events after surgical coronary revascularization. <i>JTCVS Open</i> , 2022 ,	0.2	2
29	Bypass Grafting and Native Coronary Artery Disease Activity.. <i>JACC: Cardiovascular Imaging</i> , 2022 ,	8.4	2

28	Rivaroxaban as Therapy for Saphenous Venous Graft Failure due to Venous Outflow Mismatch.. <i>Case Reports in Cardiology</i> , 2022 , 2022, 9729989	0.6	
27	Platelet-derived microvesicles regulate vascular smooth muscle cell energy metabolism via PRKAA after intimal injury.. <i>Journal of Cell Science</i> , 2022 ,	5.3	0
26	Ticagrelor versus aspirin 2 years after coronary bypass: Observational analysis from the TARGET trial.. <i>Journal of Cardiac Surgery</i> , 2022 ,	1.3	1
25	Ticagrelor versus aspirin and vein graft patency after coronary bypass: A randomized trial.. <i>Journal of Cardiac Surgery</i> , 2021 ,	1.3	1
24	Cardiovascular Risk Profile, Presentation and Management Outcomes of Patients with Acute Coronary Syndromes after Coronary Artery Bypass Grafting.. <i>Current Problems in Cardiology</i> , 2021 , 101078	17.1	0
23	Procedure and Clinical Success of Drug-Coated Balloon Fistuloplasty of the Drainage Vein in Dysfunctional Native Arteriovenous Fistulas.. <i>Journal of Interventional Cardiology</i> , 2021 , 2021, 8266673	1.8	
22	Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Prior Coronary Artery Bypass Graft: Current Evidence and Future Perspectives.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 753250	5.4	0
21	CT angiography for coronary artery bypass graft surgery. 10-18		2
20	Light-Activated Vascular Anastomosis. <i>Surgical Innovation</i> , 155335062211043	2	
19	External Support for Saphenous Vein Grafts in Coronary Artery Bypass Surgery. <i>JAMA Cardiology</i> ,	16.2	0
18	Protein O-GlcNAcylation in cardiovascular diseases. <i>Acta Pharmacologica Sinica</i> ,	8	0
17	The art of selection in coronary bypass grafting. <i>European Heart Journal</i> ,	9.5	0
16	Diagnostic and Management Strategies in Patients with Late Recurrent Angina after Coronary Artery Bypass Grafting.		1
15	Systemic delivery of clopidogrel inhibits neointimal formation in a mouse vein graft model. 2022 , Publish Ahead of Print,		
14	Current intraoperative storage and handling practices of autologous bypass conduit: A survey of the royal australasian college of surgeons. 9,		
13	Saphenous Vein Graft. 2022 , 28, 42-46		0
12	Microfluidic bioprinting of tough hydrogel-based vascular conduits for functional blood vessels. 2022 , 8,		2
11	Defective autophagy triggered by arterial cyclic stretch promotes neointimal hyperplasia in vein grafts via the p62/nrf2/slc7a11 signaling pathway. 2022 , 173, 101-114		1

- 10 Cerium dioxide nanoparticles modulate antioxidant defences and change vascular response in the human saphenous vein. **2022**, ○
- 9 CANLPH Skoru ile Safen Ven Greft Hastalar Arasındaki İlişi. ○
- 8 Revascularizaciñ arterial con doble mamaria. Riesgos y beneficios. **2022**, ○
- 7 Left Internal Mammary Artery as an Endocrine Organ: Insights Into Graft Biology and Long-term Impact Following Coronary Artery Bypass Grafting. **2023**, 98, 150-162 ○
- 6 Beyond CFD: Emerging methodologies for predictive simulation in cardiovascular health and disease. **2023**, 4, 011301 ○
- 5 Doppler Ultrasound Selection and Follow-Up of the Internal Mammary Artery as Coronary Graft. **2023**, 11, 66 ○
- 4 Perivascular patch using biodegradable polymers: Investigation of mechanical and drug elution characteristics. **2023**, 105853 ○
- 3 Fate mapping RNA-sequencing reveal Malat1 regulates Sca1+ progenitor cells to vascular smooth muscle cells transition in vascular remodeling. **2023**, 80, ○
- 2 Graft thrombosis after coronary artery bypass surgery and current practice for prevention. 10, ○
- 1 Venous External Support in Coronary Artery Bypass Surgery: A Systematic Review and Meta-Analysis. **2023**, 48, 101687 ○